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Abstract 
Tuberculous meningitis (TBM) is a type of extrapulmonary tuberculosis (TB) which leads to 
inflammation of the meninges through small lesions called Rich foci. TBM represents 1% of total 
TB disease, with the age of onset being around 2-5 years of age. Disease development remains 
poorly understood, including the mechanism of dissemination across the blood-brain barrier.  
This study concentrated on the involvement of the host genome in TBM susceptibility. We 
hypothesised that multiple common variants of moderate effect size are more likely to influence 
TBM susceptibility than rare variants of large effect. The SAC are a 5-way admixed population 
with genetic contributions from European, East Asian, South Asian, Bantu-speaking African and 
KhoeSan groups.  
Two technologies were used to genotype single nucleotide polymorphisms (SNPs) of varying 
frequency: exome sequencing and the Illumina® Multi-Ethnic Genotyping Array (MEGA). Exome 
sequencing involves capture of only the protein-coding regions of the human genome, constituting 
approximately 1% of the genome. The depth of coverage of exome sequencing enabled the 
detection of coding SNPs of lower frequency (<1%) which were assessed for association with 
TBM susceptibility. Ten TBM cases and 10 healthy controls were exome sequenced, with all study 
participants being from the SAC population.  
Gene set association tests SKAT-O and SKAT Common Rare were used to assess the association 
of rare SNPs and the cumulative effect of both common and rare SNPs with susceptibility to TBM, 
respectively. The SKAT-O analysis included 8 322 gene sets comprising 16 728 SNPs, which did 
not yield any associations with TBM susceptibility. Ingenuity Pathway Analysis (IPA) of the top-
hits of the SKAT-O analysis showed that NOD2 and CYP4F2 are both important in TBM 
pathogenesis and highlighted these as targets for future study. The SKAT Common Rare analysis 
included 13 270 gene sets comprised of 53 239 SNPs and was CCP110 associated (p = 5.89x10-6) 
with TBM susceptibility. In addition, a number of top-hit genes ascribed to the development of the 
central nervous system (CNS) and innate immune system regulation were highlighted. 
The role of common variants (>5%) in TBM susceptibility were assessed by conducting a genome-
wide association study (GWAS). A total of 123 TBM cases, 400 pulmonary TB (pTB) cases and 
477 healthy controls were genotyped on the MEGA array. A GWAS comparing 114 TBM cases 
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to 395 healthy controls showed no association with TBM susceptibility. A second analysis 
comparing 114 TBM cases to 382 pTB cases was conducted to investigate variants associated with 
different TB phenotypes. No significant associations were found with progression from pTB to 
TBM. 
This study represents the first exome sequencing and GWAS of a TBM cohort and has identified 
a single previously undescribed association with TBM susceptibility. These results further our 
understanding of TBM in terms of both SNPs and genes that influence susceptibility. In addition, 
a number of candidate genes involved in innate immunity have been identified using IPA for 
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Opsomming 
Tuberkuleuse meningitis (TBM) is 'n vorm van ekstra-pulmonêre tuberkulose (TB) wat lei tot 
inflammasie van die meninges deur middel van die vorming van klein letsels bekend as Rich 
fokusse. TBM verteenwoordig 1% van die totale TB epidemie, met ‘n aanvangsouderdom van 
ongeveer 2-5 jarige ouderdom. Die ontwikkeling van die siekte, asook die meganisme van 
beweging van bakterieë oor die bloed-breinskans, word huidiglik nie volkome verstaan nie.  
Hierdie studie het die rol van die gasheer genoom in TBM vatbaarheid ondersoek. Die hipotese 
was dat daar ‘n groter waarskynlikheid is dat veelvuldige algemene variante met ‘n matige  
effekgrootte ‘n rol sal speel in TBM vatbaarheid as raar variant met ‘n groter effekgrootte. Die 
SAK het genetiese bydraes van 5 verskillende bevolkings, naamlik Europese, Oos-Asiatiese, Suid-
Asiatiese, Bantu-sprekende Afrikane en KhoeSan groepe. 
Twee tegnologieë was gebruik om enkel nukleotied polimorfismes (ENPs) van wisselende 
frekwensie te genotipeer: eksoom volgordebepaling en die Illumina® Multi-Ethnic Genotyping 
Array (MEGA). Eksoom volgordebepaling ondersoek slegs proteïen koderende areas van die 
menslike genoom, wat ongeveer 1% van die genoom uitmaak. Die diepte van dekking van die 
eksoom volgordebepaling het die opsporing van koderende ENPs met lae frekwensies (<1%) 
moontlik gemaak en hierdie variante se assosiasie met TBM vatbaarheid is geëvalueer. Eksoom 
volgordebepaling is uitgevoer op 10 TBM pasiënte en 10 gesonde kontroles van die SAK 
bevolking. 
Die geen-stel assosiasie toetse SKAT-O en SKAT Common Rare was gebruik om die assosiasie 
van skaars ENPs sowel as die kumulatiewe effek van beide algemene en skaars ENPs met TBM 
vatbaarheid te evalueer. Die SKAT-O analise het 8 322 geen-stelle, bestaande uit 16 728 ENPs, 
ingesluit wat nie enige assosiasies met TBM vatbaarheid opgelewer het nie. Ingenuity Pathway 
Analysis (IPA) van die gene, aangedui deur die SKAT-O analise, het getoon dat beide NOD2 en 
CYP4F2  belangrike rolle in TBM siekte ontwikkeling speel en daarom kandidate vir toekomstige 
studies is. Die SKAT Common Rare analise het 13 270 geen-stelle, bestaande uit 53 239 ENPs, 
ingesluit en CCP110 was geassosieer (p = 5.89x10-6) met TBM vatbaarheid. Verder is 'n aantal 
gene betrokke by die ontwikkeling van die senuweestelsel en regulasie van die aangebore 
immuunsisteem uitgelig.   
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Die rol van algemene variante (> 5%) in TBM vatbaarheid was ondersoek deur 'n genoom-wye 
assosiasie studie (GWAS) uit te voer. 'n Totaal van 123 TBM gevalle, 400 pulmonêre TB (PTB) 
gevalle en 477 gesonde kontroles is genotipeer op die MEGA. Die GWAS analise, wat 114 TBM 
pasiënte met 395 gesonde kontroles vergelyk het, het nie enige assosiasie met TBM vatbaarheid 
gevind nie. 'n Tweede analise wat 114 TBM pasiënte met 382 PTB pasiënte vergelyk het was 
uitgevoer om assosiasie van variante met verskillende TB fenotipes te ondersoek. Geen assosiasie 
met progressie vanaf pTB tot TBM was gevind nie.  
Die huidige studie verteenwoordig die eerste eksoom volgordebepaling en GWAS van ‘n TBM 
groep en het ‘n enkele voorheen onbeskryfde assosiasie met TBM vatbaarheid geïdentifiseer. 
Hierdie resultate bevorder ons begrip van TBM in terme van ENPs sowel as gene wat 
siektevatbaarheid beïnvloed. Daarbenewens was 'n aantal gene betrokke by aangebore immuniteit 
met behulp van IPA geïdentifiseer vir verdere genotipiese en funksionele ondersoeke. 
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Chapter 1: Introduction  
1.1 Global Epidemic 
Tuberculosis (TB) ranks alongside human immunodeficiency virus (HIV) as the leading causes of 
death from infectious agents and remains a major global health threat [2]. In 1993, the World 
Health Organisation (WHO) declared TB a global public health emergency. An estimated 9.6 
million TB cases and a further 1.5 million deaths due to TB were reported in 2014 [1]. By the year 
2014, health care initiatives had improved, to varying degrees, in many countries, but global 
statistics remained virtually unaltered, with many developing countries still greatly affected by the 
disease as shown in Figure 1.1.   
 
Figure 1.1:  Estimated TB incidence rates worldwide in 2014. Mainly developing countries are affected by 
the disease, with developed countries still being affected but with a far decreased incidence. Adapted 
from [2]. 
The majority of TB incident cases were from developing countries with Asian and African 
countries having the highest incidences. The six countries with the highest number of first 
occurrence cases in 2014 were India, Indonesia, China, Nigeria, Pakistan and South Africa, 
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respectively [2]. The causative agent of TB disease is Mycobacterium tuberculosis (M.tb) and 
inquests into TB disease aetiology found a complex interaction between factors of the bacterium, 
human host and the environment [3, 4].  
 
1.2 The impact of TB in South Africa 
South Africa has one of the highest TB incidence and subsequent mortality rates in the world. This 
is in part due to a high prevalence of HIV nationwide (19.1% in 2013) [5]. The complication of 
HIV has hindered progress towards lowering the national TB incidence rate as immuno-
compromised individuals are more susceptible to TB disease [6]. TB can be treated successfully, 
but despite South Africa’s 78% treatment success rate, the death rate from the disease remains 
high, the population has poor adherence to treatment regimens and the spread of multi- (MDR) 
and extensively drug resistant (XDR) strains has placed a massive burden on the country’s already 
over-taxed medical resources [7].  
In 2014 the Western Cape Province had the fourth highest incidence rate in the country with 710 
new cases per 100 000 [8]. The province with the highest incidence rate was KwaZulu-Natal 
Province with an incidence rate of 1076 per 100 000. The estimated TB incidence for the country 






Figure 1.2: TB incidence rates (per 100 000) in South Africa showing the different proportions of TB 
incidence. Adapted from [9]. 
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1.3 Tuberculous Meningitis  
1.3.1 Background 
Tuberculous meningitis (TBM) is a form of extrapulmonary TB leading to severe meningeal 
inflammation through small lesions called Rich foci [10]. The causative agent remains the same 
as for pulmonary TB (pTB), but the definitive process of dissemination has not yet been elucidated 
[11]. TBM infections represent a minimal proportion of total TB infection, approximately 1% [12]. 
Additionally, TBM constitutes only 5-15% of all reported extrapulmonary TB cases worldwide, 
yet still remains the form of TB that has the highest mortality rate at 20 - 25%. Many survivors 
suffer from high rates of neurological sequelae as a result of the disease [13, 14]. The approximate 
TBM incidence rate in the Western Cape was 31.5/100 000 in children under the age of 1 year in 
1992 [15]. This figure has not changed, despite the common practice of neonatal vaccination using 
Bacille Calmette-Guérin (BCG) [16], leading health practitioners to question its efficacy in 
immunisation against the disease.        
 
1.3.2 Pathogenesis 
TBM is the most severe form of TB owing to its high mortality rate and is most frequently observed 
in children under the age of 5 years [11, 17]. TBM often develops within 3 months post initial 
infection and outcome is generally very poor, despite modern anti-tuberculosis drug regimens [16, 
18]. Survivors of the disease frequently suffer from debilitating neurological sequelae such as 
cognitive disabilities, optic atrophy and motor system deficits [19]. 
TBM pathology commences with the inhalation of M.tb, which is subsequently ingested by 
alveolar macrophages, where immune system inflammation is initiated [19]. Following this, there 
is increased inflammation in the lung and subsequent dissemination to the lymphatic system where 
a short period of bacteraemia occurs which can lead to the haematogenous spread of the bacterial 
infection to the meninges and other organs [20, 21]. Haematogenous dissemination leads to the 
escape of the bacteria from blood vessels in the sub-arachnoid space, located in the meninges, and 
subsequent inflammation of the surrounding tissue. The meninges are a protective layer 
surrounding the brain and spinal cord which acts cooperatively with the cerebrospinal fluid (CSF) 
to protect against mechanical injury and maintain blood supply [12]. In the case of dissemination 
to the meninges, small sub-pia mater foci are formed. These foci are named Rich foci after the 
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original studies done by Rich and McCordick on guinea pigs and rabbits [21, 22]. Rich foci are 
caseous and granulomatous in nature and can be found in either the brain cortex, meninges or 
spinal cord [10, 20]. Rich foci most often follow the blood vessels along their length. Rich and 
McCordick defined TBM and miliary TB as two independent diseases, due to cases of miliary TB 
where TBM did not develop even though many other organs contained tubercles. Even if 
tubercules were found in the meningeal region, this would often not lead to the development of 
TBM, suggesting that miliary TB and TBM were independent diseases [22]. Other researchers 
believe that the two diseases share a pathophysiological relationship where the Rich focus remains 
a central factor, but that miliary TB is an exacerbated form of dissemination to other organs [19]. 
Additionally, the Rich focus mode of entry does not explain the frequent association of miliary TB 
and TBM [23]. Donald et al. (2005) concluded that miliary TB assists in TBM development in 
children and equally increases the chance of Rich focus development and resultant rupture, leading 
to TBM [20]. 
The second phase of TBM development involves the rupture of the Rich focus into the 
subarachnoid space causing meningitis which, if untreated, can lead to serious neurological 










In other forms of bacterial meningitis, a focal point such as the Rich focus is not observed; instead, 
direct haematogenous spread takes place [23].  
Figure 1.3: The layers of the meninges depicting the Arachnoid layer, pia mater and blood vessels that aid 
in the haematogenous dissemination of TBM. Adapted from [24] 
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Following the release of M.tb from the granulomatous Rich foci into the sub-arachnoid space, a 
dense exudate forms which can be observed on magnetic resonance imaging (MRI) brain scans 
along with abnormal meningeal enhancement also seen using imaging technologies. The exudate 
contains many lymphocytes, plasma cells and macrophages due to the high bacterial load in the 
area and develops around arteries, cranial nerves and the spinal cord [20, 21, 24]. CSF drainage is 
therefore impaired and outflow prevented, leading to increased intracranial pressure, 
hydrocephalus, ischemia and infarction [19]. Rich foci are not commonly found in the lower brain 
regions in close proximity to the exudate. Instead the exudate is thought to be located in the basal 
areas of the brain due to normal CSF flow patterns before blockage occurs [22]. Vasculitis can 
also occur of both large and small blood vessels leading to stroke-like symptoms in some patients 
and may also result in paralyses such as hemiplegia and paraplegia [21]. CSF flow restriction 
therefore results in the severe and debilitating neurological sequelae observed [19, 21, 23]. It is at 
this point when many neurological symptoms are often observed by the patient with disease 
progression too advanced and thus poor outcomes [25].  
 
1.3.3 Bacterial Migration 
One of the most contested points in TBM research is the mechanism of bacterial migration from 
the bloodstream across the blood-brain barrier (BBB). The BBB is composed of endothelial cells 
arranged in tight junctions surrounded by a basement membrane and astroglial end-feet [26]. The 
unique structure of the BBB allows for efficient isolation of the Central Nervous System (CNS) 
from the rest of the circulatory system (Figure 1.4)  [27].  
Through the study of other forms of meningitis three major mechanisms of migration across the 
barrier have been elucidated: transcellular, paracellular and ‘Trojan Horse’ migration [10]. 
Organisms such as Haemophilus influenzae use the transcellular method of migration which 
involves binding to the endothelial cells of the BBB through host laminin receptors via expression 
of phosphorylcholine to mimic platelet-activating factor, a molecule readily allowed to cross the 
BBB [28]. The Trojan Horse mechanism is a hallmark observed in fungal meningitis where 
traversal of the membrane depends on inositol, found in high concentrations in human and animal 
brains  [29]. Considering the advanced inositol metabolism of mycobacteria, this represents a 
plausible method of traversal for mycobacterial species [10].  
Stellenbosch University  https://scholar.sun.ac.za
Chapter 1: General Introduction 
6 | P a g e  
 
In vitro studies have shown that M.tb infected monocytes cross the walls of alveoli more efficiently 
than uninfected ones or single mycobacteria [30]. While the hypothesis of BBB traversal through 
infected monocytes may seem plausible, a major flaw is that during the onset of TBM such cellular 
traffic is heavily restricted across the BBB thereby limiting access to the CNS [27]. Early studies 
showed that free M.tb organisms can invade the CNS without the need for encapsulation and 
protection by monocytes [31]. More recent studies in murine models with Integrin beta-2 (ITGB2) 
[also known as CD18] knockouts corroborated these findings [32]. M.tb can infect host microglia 
which are localised in the CNS [33]. Microglia therefore perform a function similar to that of a 
macrophage as a host phagocytic cell in the CNS, suggesting that microglia provide a suitable 














Molecules upregulated during early TBM infection may play a role in TBM dissemination to the 
meninges and it was found that heparin-binding haemagglutinin (HBHA) adhesin is used by M.tb 
Figure 1.4: The structure of the BBB. (a.) Structure and transporters of the endothelial cells of the BBB. 
(b.) Depiction of the interaction between astroglial end-feet and endothelial cells needed for maintenance 
of the BBB. Adapted from [26]. 
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to bind to the BBB’s structurally integral epithelial cells using a C-terminal domain [34]. HBHA 
deficient strains have an ineffective ability to escape from the lungs, therefore suggesting a role 
for HBHA in the spread of M.tb, and for strain differences in disease severity [35, 36]. Several 
other molecules are used by M.tb in order to traverse the BBB, namely matrix metalloproteinase-
9 (MMP-9) and vascular endothelial growth factor (VEGF) [37]. MMP-9 is commonly found in 
the basement membrane and functions in BBB degradation. It is not often present in the CSF but 
may be upregulated in conjunction with tumour necrosis factor-α (TNF-α) during early TBM 
development. VEGF is a multifunctional cytokine that is involved in inflammation, angiogenesis 
and stimulation of MMP-9 secretion. It was associated with meningitis, particularly in TBM 
patients (mean ± SD = 144.4 ± 75.1 pg/ml, p < 0.01) [38].   
In vitro modelling of processes such as BBB invasion by bacteria enhance our understanding of 
the molecular mechanisms involved. In order to determine the method of invasion of brain 
microvascular endothelial cells, a major component of the BBB, an invasion assay was set up using 
a monolayer of primary endothelial cells incubated with both M.tb and the non-virulent strain M. 
smegmatis (Figure 1.5) [39]. M.tb invaded and traversed the BBB model with far greater efficiency 
than did M. smegmatis. This was achieved through host-cell actin cytoskeletal rearrangements 
hypothesised to occur through interaction between bacterial virulence factors and host recognition 
receptors. Gene-expression analysis found that 33 genes in a genetic island of the mycobacterial 
genome were upregulated, 18 of which belonged to a previously described island (Rv0960-
Rv1001).  The BBB remains a crucial barrier to separating the brain from the rest of the circulatory 
system. Despite the fact that one can have TBM and not have BBB breach or damage, it still 
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1.3.4 Symptoms of TBM 
The symptoms associated with TBM vary and are broad, which complicates diagnosis. Many cases 
of TBM begin with non-descript symptoms and are often diagnosed too late, once brain damage 
has already occurred [11]. One of the points of differentiation between TBM and diseases with 
similar etiology is the prolonged persistence of non-specific symptoms [40]. TBM generally 
develops in the 3 months following primary infection, and pulmonary involvement may play a role 
in only a small subset of patients [20]. Symptom presentation differs between children and adults 
with TBM. Adults generally present with non-descript symptoms common to all forms of 
meningitis, including fever, headaches, neck-stiffness, focal neurological deficits, changes in 
behaviour and altered consciousness. In these patients pulmonary involvement varies between 30 
to 50% [41, 42].  
In children, symptoms are similar to those of adults with the addition of abdominal involvement 
such as nausea and associated vomiting. Neurological symptoms are also slightly altered as 
headaches are not as frequently observed in children as in adults but seizures are more likely. 
Figure 1.5: (A) Invasion assay: Primary endothelial cells line the bottom of a flask incubated with a 
mycobacterial suspension of either species. (B) Traversal Assay: infant endothelial cells were grown on 
trans-well inserts. Separate access was provided for the upper (blood side) and lower (brain side) 
compartments. The monolayer was incubated with a mycobacterial suspension to induce traversal to the 
upper compartment. After 48h the contents of the lower compartment was plated to determine the 
number of mycobacteria that traversed the membrane. Adapted from [40] 
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However, neurological symptoms depend on disease stage and progression [43, 44]. A particular 
feature of TBM in children appears to be a close association between TBM and miliary TB. This 
relationship is thought to exist as a result of extensive haematogenous dissemination in children 
which increases the likelihood of Rich focus development [20]. Symptoms in both adults and 
children have been shown to present acutely, with symptoms usually observed later in pulmonary 
disease often noted much earlier in TBM [40]. Disease progression modifiers such as 
mycobacterial strain genotype, drug resistance status of the invading strain, HIV and TB co-
infection and BCG immunisation status do not consistently influence disease presentation nor 
disease acuteness.    
There are several stages of disease that allow physicians to determine the correct treatment regimen 
for the patient. This staging system follows Glasgow Coma Scores associated with tell-tale 
observable traits. Grade I TBM is described as orientated and fully alert without any signs of 
neurological damage. Grade II is associated with a Glasgow coma score of 11-14/15 with some 
neurological deficits. Grade III has a Glasgow coma score of <10 and may include focal 
neurological deficits [45].        
 
1.3.5 Diagnosis of TBM 
Central to any TBM diagnostic or treatment regimen is the need for early diagnosis and treatment 
for better outcomes and patient survival. Owing to the non-definitive symptoms of TBM, diagnosis 
proves extremely challenging and requires extremely sensitive and specific diagnostic tests. One 
of the primary indicators for TBM diagnosis is symptom persistence for longer than 5 days [46]. 
This indicator scale is central to the widely used Thwaites Diagnostic Index which was described 
as 86% sensitive and 79% specific for diagnosis in Vietnamese adults. Subsequently this indexing 
system has been used in several other countries with sensitivities ranging between 96-98% and 
specificities from 68-88% [47–49]. Testing in a variety of different populations exposed the major 
disadvantage of the Thwaites Diagnostic Index, being the significant number of false positives (12 
out of 86) for patients with cryptococcal meningitis thus lowering the sensitivity and specificity to 
78% and 43% respectively [50].  
Diagnostic methods for TBM vary in effectiveness, time to result and cost, with each technology 
having specific strengths. TBM is primarily diagnosed by microscopy using Ziehl-Neelsen 
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staining techniques for acid-fast bacilli in the CSF. However, the results obtained are usually poor, 
indeterminate and varied where sensitivity rarely exceeds 60% [46, 51]. Nucleic acid amplification 
tests (NAATs) are commercially available rapid methods of detection. NAATs should only be 
used in conjunction with other diagnostic methods and cannot be used to rule out TBM [52], due 
to the low sensitivity of the test at 56% (95% CI: 46%-66%), although specificity is 98%. The 
major challenge is the acquisition of sufficient volumes of nucleic acid for tests due to the low 
number of bacilli and the presence of CSF amplification inhibitors [23]. Real-time polymerase 
chain reaction (rtPCR) technology has led to the development of a GeneXpert assay to 
simultaneously detect M.tb and rifampicin resistance, critical for MDR pTB detection [53, 54]. 
The Xpert MTB/RIF assay shows great promise with sensitivity values of 80.4%. This assay has 
yet to be tested on CSF samples and its efficacy in TBM diagnosis is unknown [55]. The TB whole 
blood test, Interferon-γ release assay (IGRA), can be used to diagnose pTB but cannot differentiate 
between latent and active TB [56]. These assays are possible diagnostic tools for TBM but low 
sensitivities (50-70%) have hindered progress for a definitive TBM diagnostic test [55, 57, 58].  
Adenosine deaminase (ADA) catalyses the deamination of adenosine to inosine and ammonia [59]. 
ADA has two isoforms namely ADA1 and ADA2, where ADA2 localises to monocytes and plays 
a role in immature T-cell activation [60]. ADA2 is the major component of total ADA 
concentration observed in TBM and may be a useful diagnostic marker to distinguish between 
forms of meningitis due to the significant upregulation of  ADA2 levels in TBM compared to other 
forms of meningitis [61–65]. Cut-off values used affect sensitivities and specificities ranging 
between 57-96% and 78-87%, respectively [60, 66]. Radiographic diagnosis is often used in 
conjunction with other tests. However, no radiographic findings can be specifically attributed to 
TBM to enable definitive diagnosis. The common features of TBM that can be observed by 
radiological imaging include basal meningeal enhancement, hydrocephalus, and infarctions of the 
brain parenchyma and brain stem [67]. Diagnosis of TBM using computer tomography (CT) scans 
through observations of basal meningeal enhancement, tuberculoma or both were 89% sensitive 
and 100% specific for TBM [68].  
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1.3.6 Treatment of TBM 
Treatment regimens recommended for TBM follow a similar course to that of pulmonary TB, with 
emphasis placed on early treatment initiation. The course recommended by the Centres for Disease 
Control and prevention (CDC) and the American Thoracic Society is initiated with a 2 month 
induction period in which isoniazid, rifampicin, pyrazinamide and ethambutol are used in 
conjunction [69]. This is followed by a longer period of 7-10 months of isoniazid and rifampicin 
administration as a maintenance regimen. Due to the rare phenotype of TBM disease, a clinical 
trial has not yet been conducted to elucidate the correct duration of treatment and optimal drug 
regimen. Therefore treatment durations, dosages and the drugs used for TBM are all extrapolated 
from those used to treat pTB [23]. Typical phenotypic presentations before, during and after 
treatment are shown in Figure 1.6.  
The advantage of the drugs in the regimen for pulmonary TB is that both isoniazid and 
pyrazinamide are readily able to cross the BBB [70]. This is an important consideration, as the 
BBB has the ability to limit CSF drug concentrations. Rifampicin and ethambutol, in contrast, 
display reduced CNS penetration despite still playing a role in TBM treatment [71]. The treatment 
of drug-resistant strains relies mostly on the specific drugs that they remain sensitive to and often 
leads to an increase in the number of drugs used in the treatment regimen. No guidelines exist for 
the treatment of drug-resistant TBM and therefore current MDR TBM regimens are extrapolated 
from the guidelines for pulmonary TB [72].  
Several studies have outlined the use of adjunctive corticosteroids in TBM treatment as it is 
associated with a reduction in mortality, although the mechanism is unknown. Corticosteroids 
assist in the alleviation of the inflammation associated with TBM and thus may facilitate the 
transport of drug compounds across the BBB [73, 74].  
Recent developments in treatment regimen formulation have led to the inclusion of thalidomide 
therapy at Tygerberg Hospital in Cape Town, South Africa [75]. Thalidomide, a known TNF-α 
inhibitor, is included in regimens at a dosage of 3-5mg/kg/day for a duration of 6 months in cases 
presenting with TB pseudoabscesses and mass lesions. TB pseudoabscesses are thought to form 
part of immune reconstitution inflammatory syndrome (IRIS) and can be worsened with 
concurrent HIV infection. Thalidomide stimulates natural killer (NK) cells and leads to the 
inhibition of lymphocyte apoptosis [76]. Cytokine production of interleukin-4 (IL-4) and IL-5 are 
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increased whereas interferon-γ (IFN-γ) production is decreased along with CSF TNF-α during 
thalidomide treatment.  Thalidomide use in HIV positive TB patients has been shown to enhance 
HIV-specific CD8 T-cell activity but has no effect on viral numbers. As thalidomide functions in 
abscess reduction, its recommended use is only in patients experiencing neurological compromise 
as a result of TB pseudoabscesses and mass lesions, approximately 80% of participants had a good 
outcome, with a 3.8% mortality rate, significantly lower than previous mortality statistics [77].     
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Figure 1.6: Factors influencing TBM presentation and symptoms. Arrows indicate contributions from the environment, host genetics, immune system and 
bacterial strain. The regulation of variables during treatment and post-treatment phases are also represented showing the outcomes of treatment regimens. 
Adapted from [78] 
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1.4 Models used in the study of TBM 
Models provide a cost-effective and ethically amenable route of studying disease dynamics and 
pathophysiology. Each model has advantages and disadvantages to its use and is suitable for 
different aspects of disease. Disease progression can be studied for the lifetime of the model, their 
genetic history is known, and knockout models are easy to create [78]. Conclusions can be 
extrapolated to humans depending on physiological similarities.  Several models have been used 
to study TBM, from mouse models to zebrafish and synthetic models. All have been used to 
elucidate specific dynamic aspects of the disease.  
1.4.1 Rabbit Models 
The first animal models used to study TBM were rabbits and guinea pigs [22]. An investigation 
into the role of TNF-α was performed using intracranial injection of M. bovis Ravenal into a rabbit 
model [79]. An acute inflammatory response was induced in the CSF and allowed for the 
identification of viable mycobacterial cells. Distinct clinical symptoms of TBM were noted in the 
rabbit including the identification of granulomas and dissemination to other organs. A sub-acute 
model was used to evaluate thalidomide treatment response and the efficacy of a recombinant 
vaccine for the treatment of TBM [80–82]. Investigations with different clinical isolates [83] 
demonstrated differences in bacillary loads between the strains in the CSF and brain parenchyma 
and elevated levels of TNF-α and leukocytosis, both of which are observed in human disease. It 
was concluded that the differences noted between the strains could be attributed to the production 
of a phenolic glycolipid (PGL), a known virulence factor.  
1.4.2 Murine Models 
Several mouse models have been used in the study of TBM through the use of intracranial injection 
to invoke meningeal inflammation and a similar immune response to that seen in humans. BALB/c 
and DBA/2 mice inoculated with M. bovis BCG Montreal to detect microglial activation in the 
brain demonstrated viable growth of mycobacteria in the meninges and surrounding areas of the 
brain [84]. Models have also been developed or intracranial inoculation of H37Rv into C57BL/6 
mice to elicit an inflammatory response similar to that seen in humans that leads to leukocytosis 
[85]. However, no neurological defects could be modelled and no granulomas were observed. 
Intratracheal infection was used to infect BALB/c mice with 3 clinical strains of M.tb to observe 
the disseminatory capabilities of each strain and the related symptoms exhibited by each model 
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[13]. Inflammation and extensive dissemination in the cerebral parenchyma and surrounding 
meninges were observed in the TBM clinical strains when compared to pulmonary TB clinical 
isolates which displayed strain-dependent dissemination.  
1.4.3 Zebrafish Models 
Zebrafish models have been useful in several diseases due to their genetic similarity to humans 
(70%) [86]. Dissemination of M. marinum in zebrafish has elucidated pathways involved in 
pathogenesis, with granuloma formation in the meninges occurring in approximately 70% of cases 
and occasionally in the brain parenchyma as well [10]. Embryos were also used to model 
infiltration into the CNS through the BBB after inoculation at 3 sites: caudal vein, hindbrain 
ventricle and brain parenchyma. Each model displayed high bacterial loads in the brain tissue, 
whether embryos were infected before or after BBB formation. This illustrated that bacteria were 
able to cross the BBB with high efficiency, although the method remains unconfirmed. 
Granulomas observed in adult zebrafish were similar to those in humans in that they develop in 
close relation to the meninges and surrounding brain tissues, providing a useful proxy for 
modelling early stage TBM infection. 
Although each of the above models may reproduce some aspects associated with TBM, no model 
has been described that cumulatively models disease progression, immune responses and the 
resultant neurological defects seen in human TBM. Importantly, each of these models is artificially 
generated through bacterial injection and therefore lack comparability with human disease.      
1.5 Immune Response to TBM 
1.5.1  Toll-Like Receptors 
Human immune responses to TBM are governed by cell-mediated immunity. The process is 
initiated by recognition of mycobacterial cell wall carbohydrates and proteins via specialised 
receptors such as the toll-like receptors (TLRs) [87]. TLRs recognise pathogen-associated 
molecular patterns (PAMPs) and activate signalling pathways to stimulate the innate immune 
response, cytokine production and the adaptive immune system [88]. Mycobacteria are typically 
recognised by TLR1, -2, -4 and -6 which require interaction with the adaptor protein myeloid 
differentiation primary response 88 (MyD88) to facilitate the production of nuclear factor κ B 
subunit 1 (NFκB). Importantly, lipoarabinomannan and M.tb lipoprotein are both recognised by 
TLR2 [89]. TLR2 is highly expressed on cells of the haematopoietic system such as B and T 
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lymphocytes and particularly macrophages, monocytes, granulocytes and dendritic cells. Mouse 
knock-outs have shown that TLR2 is crucial for defence and recognition of M.tb, as these mice 
displayed impaired cytokine and nitric oxide production and failed to mount an effective killing 
response [90–92]. Immune receptor pathways such as the TLR pathway provide ideal candidates 
for association studies as polymorphisms in any of the receptor genes or respective adapter protein 
genes may lead to an ineffective response.   
1.5.2 TNF-α 
One of the central cytokines in mounting an immune response against M.tb is TNF-α. TNF-α 
induces apoptosis in tumour cells and mediates a large variety of biological activities, such as 
formation and maintenance of granulomas [93]. The functions of TNF-α display concentration-
dependent effects; when present in high concentrations TNF-α has been shown to be toxic to the 
host causing cachexia (tissue necrosis and wasting) [94]. Conversely when concentrations are low 
the protective functions are insufficient and host defence is severely compromised [79, 93, 94]. 
Rabbits inoculated with one of three TB strains induced differential levels of TNF-α. 
Mycobacterium bovis Ravenal induced the  highest levels of TNF-α and led to the development of 
acute meningitis, while rabbits inoculated with strains which induced low levels of TNF-α did not 
develop meningitis [79]. To confirm that TNF-α was directly related to meningitis development, 
a nonvirulent strain was transformed with a recombinant murine TNF-α gene and the resultant 
strain induced meningitis. Thalidomide treatment led to the inhibition of TNF-α production  and a 
reduction in leukocytosis and meningeal inflammation in the CSF [79]. Increased levels of TNF-
α and IL-1β have been associated with fever, seizures, spasticity and death, possibly due to 
induction of pro-coagulant production [79]. This in turn causes endarteritis and vessel occlusion, 
triggering the nervous system sequelae of TBM [95–97].  
Leukotriene A4 Hydrolase (LTA4H) regulates the balance between pro- and anti-inflammatory 
cytokines [93]. A homozygous CC genotype for the LTA4H rs17525495 single nucleotide 
polymorphism (SNP) leads to an anti-inflammatory phenotype which lowers TNF-α to detrimental 
levels. Conversely TT genotypes lead to a hyper-inflammatory phenotype and high TNF-α 
concentrations. Heterozygous genotypes maintain the delicate balance between the pro- and anti-
inflammatory responses  and protects against pTB and TBM in a Vietnamese population [98, 99]. 
The complex balancing mechanism model is presented in Figure 1.7. Heterozygous advantage is 
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uncommon and thus suggests that dysregulation of the inflammatory response is linked to TBM 
susceptibility [100].   
Mycobacterial PGL was found to inhibit production of TNF-α and other pro-inflammatory 
cytokines such as IL-12, IL-6 and Fas-ligand [83]. PGL is a cell-surface lipid that promotes 
phagocytosis of M.tb by host macrophages [101]. It was found that PGL participated in the 
induction of CNS inflammation through interaction with TNF-α, thereby influencing the virulence 












1.5.3 Immune cells and cytokine production 
Cytokine level fluctuations can directly alter the efficacy of the immune response to TBM and 
affect the course of the disease [18]. Cytokines in the CSF of patients typically include: TNF-α, 
IFN-γ, IL-1β, IL-6, IL-8 and IL-10, which typically display differential expression in TBM patients 
and are not typical of other forms of meningitis [102, 103]. 
Macrophages and microglia are commonly found in the meninges and surrounding blood vessels 
and have an approximate life-span of 100 days. Macrophages are found ubiquitously in the body, 
while microglia are found only in the brain [93]. The largest proportion of  microglia in the brain 
Figure 1.7: A proposed model for the two susceptible genotypes of LTA4H. 
With the homozygous SNP allele represented on the left side and the 
homozygous wild-type genotype represented on the right. Adapted from 
[98] 
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exists in the ramified state whose main function is immune-surveillance [104]. Ramified microglia 
regain their phagocytic capability by becoming reactive following a pathogen encounter. Both 
microglia and macrophages produce chemokines such as C-C motif chemokine ligand 2 (CCL2), 
CCl5, and chemokine C-X-C ligand 9 (CXCL9)/10/11 which recruit T-cells to the site of infection.  
Phagocytosis of invading mycobacteria is one of the main functions of both macrophages and 
microglia [93]. This process is receptor-mediated through cell-surface molecules. The phagosome 
fuses with a lysosome to release toxic chemicals such as nitric oxide (NO). If the phagocyte kills 
M.tb then antigens will be presented to cluster of differentiation 4 (CD4+) and CD8+ T-
lymphocytes increasing the cytokine complement to aid in bacterial clearance.   
Pathway analysis has been used to provide insight into the upregulated pathways involved in 
mounting an immune response against TBM [18]. Upregulated levels of CCL3, CCL4 CCL5, 
CXCL10 and C-C chemokine receptor 5 (CCR5) proteins were similar to that observed in patients 
with multiple sclerosis (MS). MS hinges around the demyelination of the CNS, leading to an 
increase of activated T-cells and macrophages in the CNS inducing leukocytosis and inflammation. 
This led to a hypothesis that similar treatment regimens may be used in patients with TBM to 
decrease hyper-inflammation, the aim being to reduce the number of survivors with debilitating 
neurological sequelae.  
1.6 HIV and TB Co-infection 
Owing to the rapid spread of HIV, an increase in the incidence of new TB cases has been observed. 
This comes as a direct result of the immune-compromisation of patients with HIV and has led to 
poorer prognosis and an increased risk of re-activation of latent TB infections [105, 106]. Healthy 
HIV-uninfected patients exhibit a lifetime risk of developing TB of between 10% and 20%, which 
increases in HIV-infected patients to above 20% [107]. HIV-infected patients display an 
increasingly rapid TB disease progression and likelihood of TBM development of approximately 
1 in 3 persons, when presenting with active TB [6, 42, 108]. Co-infection complicates treatment 
regimens as the risk for relapse in these individuals is greatly increased and subsequently leads to 
increases in drug-resistance [109]. Co-infection does not affect anti-tuberculosis drug activity 
despite the immunosuppressed nature of the host immune system [42]. HIV does not alter the 
presenting symptoms of TBM patients, but instead may alter the number and nature of secondary 
neurological complications associated with the disease [25]. Co-infected patients display fewer of 
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the defining pathological features of TBM, with post-mortem examinations finding fewer basal 
exudates and larger numbers of acid-fast bacteria in the meningeal and cerebral parenchymal 
regions [42]. Other features include lower leukocyte counts in the CSF due to the targeted attack 
on CD4+ T-cells by the virus which may explain the greater number of acid-fast bacilli observed 
in the CSF of co-infected patients, and the increased likelihood of concurrent miliary TB and TBM. 
HIV infection status has been associated with increased disease severity in patients and thus 
mortality in these patients may exceed 60% [110, 111].  
Studies relating to the complex relationship between HIV and TBM have been few. A study using 
96 co-infected and 432 HIV-infected patients was done in Southern Vietnam, showing associations 
with male sex (p < 0.001), age (p < 0.001), weight (p = 0.018), Glasgow coma score (p = 0.018) 
and peripheral leukocytes and neutrophils (p < 0.001 and 0.032 respectively), amongst others [42]. 
It was also noted that increased concentrations of aspartate transaminase and alanine 
aminotransferase in co-infected patients had potential as diagnostic markers. Interestingly several 
groups have found that co-infection with HIV did not affect patient survival nor patients with 
neurological sequelae [42, 106]. The complex relationship between HIV and TB could be 
explained by HIV’s ability to render TNF-α mediated macrophage apoptosis non-functional [112, 
113].  
1.7 Host genetics of TBM 
Historically, it was thought that TB disease was inherited but following the discovery of the 
causative bacterium, focus shifted towards the capacity of the host immunophenotype to counteract 
the pathogen [114]. Subsequent inquests into TB disease aetiology revealed a complex interaction 
between host, pathogen and environmental factors. Twin and immunological studies have 
identified a definite host genetic component, with TB heritability ranging from 36% to 80% [3, 4]. 
Several susceptibility loci for TB have been identified, mainly through candidate gene association 
studies and genome-wide linkage analyses [115]. Despite the identification of numerous 
susceptibility genes for TB, such as natural resistance-associated macrophage protein 1 
(NRAMP1), human leukocyte antigen DR beta 1 chain (HLA-DRB1) and CCL2, a large proportion 
of the heritability of this complex disease remains unidentified [14, 115]. In the case of TBM, 
many genes have been highlighted as susceptibility genes, a large proportion of which function as 
part of the innate immune system [116].    
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1.7.1 SNPs associated with TBM 
Candidate gene association studies are a popular study design to investigate genetic susceptibility 
to TBM. Usually genes thought to have a functional effect during M.tb infection are investigated. 
Candidate genes chosen often play central roles in critical immunological pathways associated 
with infection. There is some evidence for association with TBM for SNPs in the TLR and toll-
interleukin 1 receptor adaptor protein (TIRAP) genes, purinergic receptor (P2X7) and cytokine 
genes, but in all cases were population specific.  
1.7.1.1 SNPs in the TLR and TIRAP genes 
Polymorphisms in genes encoding proteins that function within the TLR pathway may lead to 
protein inactivity as they are unable to recognise targets and subsequently induce signal 
transduction. Previously, TIRAP and TLR2 SNPs have been associated with TB in a Thai but not 
an African population [117, 118]. The C allele of the TLR2 g.597T>C SNP, was found to be 
associated with TB in the Thai population (p = 0.007 [odds ratio (OR) = 2.22, 95% CI: 1.23-3.99]) 
[118]. However, the association was increased in the TBM group (p = 0.0002 [OR = 3.26, 95% 
CI: 1.72-6.18]) and was found to be strongest in the presence of miliary TB and higher grade 
neurological symptoms (p = 0.0002 [OR = 5.70, 95% CI: 1.81-18.0]). The association was found 
to be highest in individuals with a dominant 597CC homozygous genotype. Polymorphisms in 
TLR2 may affect the ability of the receptor to recognise ligands, this could be due to the inability 
to heterodimerise with either TLR1 or TLR6. Differences in allele frequency between populations 
may explain the lack of replication of the association in the African cohort [90–92]. An association 
between the g.597T>C SNP of TLR2 and the Beijing strain of M.tb was strongest of all of the 
strains tested (p = 0.001 [OR = 1.91, 95% CI: 1.28-2.86]) [116]. The Beijing strain genotype is 
considered to be one of the most virulent strains due to an intact polyketide synthase 15/1 (PKS 
15/1) gene and the production of PGL. PGL plays a role in the dissemination process as knock-out 
PGL-/- mycobacteria were less capable of dissemination than wild-type [83, 119, 120]. The 
association between the Beijing strain genotype and the TLR2 SNP demonstrates the first 
relationship between a bacterial and host genotype in TB.  
The TIRAP gene encodes a critical adaptor protein in the TLR pathway. Its biological function of 
signal mediation from TLR1, -2, -4 and -6 makes it a plausible candidate gene. Several SNPs in 
the TIRAP gene have been investigated. The T- allele of the g.539C>T SNP (S180L) is protective 
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against pneumococcal disease, malaria, and pulmonary TB in Caucasian, South American and 
African populations [121, 122].  TIRAP  SNP g.558C>T was associated with TBM patients (p < 
0.001 [OR = 3.02, 95% CI: 1.79-5.09]) [88]. Analysis of IL-6 production ex vivo showed an 
association between individuals with a 558TT genotype and a decrease in IL-6 production, 72.7 
pg/ml [95% CI: 6.7-91.2] compared to the 558CC genotype, 329.9 pg/ml [95% CI: 155.3-965.3] 
when stimulated with PAM2Cys-SKKK (PAM2). These results show that TB cases carrying the 
558TT genotype display inefficient IL-6 production, contributing to uncontrolled bacterial growth 
and eventual dissemination.  
Screening of the open reading frame (ORF) of the TIRAP gene in two South African populations, 
a Xhosa and a mixed ancestry population, found similar results to previous studies [88]. However, 
the association of g.558C>T with TBM was restricted to the mixed ancestry population in both 
heterozygous (p <  0.05), and homozygous 558TT (p = 0.02) genotypes [117]. No significant 
differences in cytokine production were observed during Lipopolysaccharide (LPS) stimulation of 
the TLR4 pathway. Instead, TNF-α levels differed between g.548G>C, a novel SNP identified, 
and g.589G>A which showed increased TNF-α than wild-type individuals in the Xhosa group, p 
< 0.05. Differences between the results of the two studies could be attributed to differences in 
allele frequencies between population groups. Differences in cytokine production can be attributed 
to different ligands used for TLR stimulation, as Hawn et al. (2006) used PAM for stimulation of 
the TLR2 pathway, whereas Caws et al. (2008) used LPS, a known TLR4 ligand [94, [117]. TLR2 
is the main recognition receptor for M.tb, which suggests that the effect of the g.558C>T SNP is 
specific to TLR2 signalling and may therefore influence the occurrence of TBM in affected 
patients.  
1.7.1.2 SNPs in the P2RX7 gene and their effect on ATP-mediated killing of mycobacteria 
The P2X7 receptor (P2RX7) is expressed on the surface of human macrophages and plays a role in 
mycobacterial defence [123]. P2RX7 is activated by extracellular ATP to induce its killing activity 
upon phagocytosed intracellular mycobacteria, acting independently from reactive oxygen and 
nitrogen-mediated killing systems [124, 125]. Activation of P2RX7 opens cation-selective 
channels mediating calcium (Ca2+) influx, this activates a caspase cascade resulting in 
mycobacterial apoptosis and the activation of phospholipase D (PLD) [126–128]. The role of PLD 
is to induce fusion between the phagosome and the lysosome containing cytotoxic enzymes [125, 
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129]. Several SNPs have been found in the P2RX7 gene, with the most common of these being 
g.1513A>C [130]. The consequential amino acid substitution affects many of P2RX7 functions, 
including the ability to create cation influxes. G.1729T>A displays a functional hindrance by 
preventing the receptor trafficking to the cell surface [131]. g.946G>A prevents ATP binding 
required for the activation of downstream caspase cascades [132]. The g.151G>T SNP results in a 
null allele [133]. The cumulative effect of these polymorphisms affects the responsiveness and 
activity of P2RX7 [134, 135].   
g.1513A>C was found to be associated with all forms of extrapulmonary TB (including TBM 
patients), but not pulmonary TB (p < 0.01 [OR = 3.8, 95% CI: 1.6-9.0]) [123]. Allelic analysis 
found that individuals who were homozygous for the 1513C allele displayed abrogated ATP-
mediated killing upon phagocytosed mycobacteria whereas heterozygotes displayed severely 
limited killing capacity. The authors posited that loss of P2RX7 could lead to unhindered spread 
of mycobacteria and subsequently higher bacterial load. A meta-analysis of g.1513A>C and the 
NG_011471.2:g.-762T>C promoter SNPs, previously found to confer susceptibility in a Gambian 
population [136], showed that A1513C was associated with TB (p < 0.00001 [OR = 1.44, 95% CI: 
1.23-1.68]) in 1044 cases and 1286 controls across 6 studies. NG_011471.2:g.-762T>C was not 
associated with TB (p = 0.97 [OR = 1.01, 95% CI: 0.70-1.44]) in 857 cases and 1068 controls. 
Similar results were observed between g.1513A>C and TB [137]. Sub-group analysis showed 
stronger association with extrapulmonary forms (p < 0.001 [OR = 1.39, 95% CI: 1.16-1.66]) with 
the 1513CC genotype found to completely ablate the ATP-mediated killing response (p = 0.012 
[OR 1.58, 95% CI: 1.13-2.22]). Contrary to this, no association was found between the g.1513A>C 
SNP and either pulmonary or extrapulmonary TB forms (p = 0.275). This result highlights the 
effect of allele frequency differences between different population groups upon association results 
[138]. 
1.7.1.3 SNPs in IFN-γ 
Interferons are proteins that are produced and exported from immune cells in response to pathogen 
recognition. IFN-γ is produced by T-helper 1 cell (Th1) lymphocytes and plays a role in 
macrophage activation [139]. Several polymorphisms in the IFN-γ gene have been studied, such 
as the g.874A>T (rs2430561) SNP, the T-allele of which was shown to confer a protective 
advantage against pulmonary TB in a South African population (p = 0.0055 [OR=1.64, 95% CI: 
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1.16-2.30]) [140]. Meta-analysis concluded that the 874T allele confers the protective advantage 
observed [140, 141]. A study in a Chinese Han paediatric female population group investigated 3 
SNPs of the IFN-γ gene, namely g.1616C>T (rs2069705), g.874A>T (rs2430561) and g.3234C>T 
(rs2069718) for association to extrapulmonary TB [142]. Their results indicated that the 874A and 
3234C alleles were both associated with extrapulmonary TB (p = 0.039 [OR = 1.53, 95% CI: 0.92-
2.54]). Additionally, the two SNPs were found to be in linkage disequilibrium (LD) (r2 = 0.987). 
Haplotype analysis showed the TTT haplotype was less prevalent in cases compared to controls, 
indicating a protective advantage (p = 0.005 [OR = 0.46, 95% CI: 0.26-0.79]). Individuals carrying 
the TTT haplotype are protected against TBM disease due to an intact IFN-γ response and 
consequent macrophage activation.  
1.7.1.4 SNPs in IL-4 
IL-4 is an anti-inflammatory cytokine that is produced by Th2 cells during immune responses 
against M.tb. IL-4 has been shown to exert its anti-inflammatory effect through the down-
regulation of IFN-γ and other Th1 related responses, which leads to deleterious effects in the host 
if unregulated [143, 144]. Two SNPs in IL-4 were found to exert protective effects against TBM 
and other forms of extrapulmonary TB, rs2243268 (p=0.005, OR=0.59 [95% CI: 0.41-0.85]) and 
rs2243274 (p=0.004 [OR=0.58, 95% CI: 0.40-0.84] [143]. The AA and GG protective genotypes 
respectively led to significantly lower production of IL-10 upon stimulation with inactivated 
H37Rv (p=0.045) and thus had a weakened anti-inflammatory response (IL-4 levels were 
unmeasurable). Efficient regulation of an anti-inflammatory response is central to mounting a 
sufficient response to TB infection. The proper maintenance of cytokine homeostasis may be key 
to controlling the dissemination observed in early TBM development.  
1.7.2 Strain Genotype Effects 
Differences in disease severity and patient outcome have been observed between M.tb strains, 
leading to investigations into the link between the most pathogenic strains and increased disease 
severity. Beijing TB strain isolates are considered to be among the most virulent, thus it is 
unsurprising that they have been associated with increased disease severity and mortality rates in 
HIV-TBM co-infected patients. Several studies have investigated the associations between strain 
genotypes and severity or likelihood of disease development in extrapulmonary TB [16, 42, 53, 
109, 116, 145–147]. Authors have hypothesised that some M.tb strains could possess increased 
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disseminatory capacity because of the interplay between the strain and host genotype related to 
polymorphisms in host TLR genes [116]. They compared the host and mycobacterial genotype 
between 187 TBM patients, 237 pTB patients and 392 controls from a Vietnamese population. 
Interestingly a protective association was found between the Euro-American lineage of M.tb and 
TBM (p = 0.009 [OR = 0.395, 95% CI: 0.193-0.806]). This suggests that the Euro-American strains 
are less capable of causing disseminated disease than other more virulent strains. In accordance 
with this, patients infected with the Euro/American strain displayed comparatively shorter disease 
courses (p = 0.039 [OR = 0.973, 95% CI: 0.948-0.999]). In further support of this theory, an 
association was found between the C allele of the g.597T>C TLR2 SNP and strains of the Beijing 
genotype, therefore patients with 597CC genotype were more likely to have TBM caused by a 
Beijing genotype strain (p = 0.004 [OR = 1.57, 95% CI: 1.15-2.15]) [116]. 
In support of the results found by Caws et al. (2008), an independent study by Kong et al. (2007) 
studying a population in Arkansas, USA found that patients infected with Beijing strain isolates 
were approximately 3 times more likely to have extrapulmonary disease as other patients infected 
with non-Beijing isolates (OR = 2.85 [95% CI: 1.33-6.12]) (p-value unavailable) [116, 146]. An 
association was also found between the Beijing strain genotype and disease in patients younger 
than 15 years old (p = 0.018 [OR = 4.47, 95% CI: 1.10-18.17]) [147]. Contrary to these results, 
two studies from South Africa found no association between invading strain genotypes and clinical 
features of TBM disease in their respective study populations [16, 148]. This could be due to 
population or design differences between the studies.  
Investigations into the relationship between HIV-TBM co-infected patients and specific strains 
aim to elucidate whether one strain in particular is more associated with co-infected TBM disease 
than any other [42, 53, 109]. HIV-TBM co-infected patients in a Vietnamese cohort have higher 
incidences of MDR-TB (p = 0.034 [OR = 12.35, 95% CI: 1.23-125.00 and mortality (p = 0.001, 
OR = 4.24 [95% CI: 2.10-8.54]), compared to HIV un-infected TBM patients [72, 109, 149]. This 
may be due to host immunosuppression as a direct result of co-infection with HIV and subsequent 
treatment regimen complication. The Beijing strain was associated with both HIV-positive status 
(p = 0.0.16 [OR = 2.95, 95% CI: 1.38-6.44]) and acquisition of drug resistance (p < 0.001 [OR = 
3.34, 95% CI: 1.87-5.95]) [109]. This suggests that Beijing isolates may more readily cause TBM 
disease in HIV-infected TBM patients and have a higher propensity for acquiring drug resistance 
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mutations independent of host HIV status. HIV further complicates TBM infection due to the 
reduction in CD4+ T-cells, diminishing the innate immune system, increasing patient susceptibility 
to M.tb infection and dissemination likelihood due to high bacterial loads [150, 151]. In contrast, 
other studies did not find that HIV-TBM co-infection altered treatment response of patients despite 
marked immunosuppression [42]. A study by Tho et al. (2012), examined the combined effects of 
drug resistance and strain genotype on HIV-TBM co-infection patient survival [53]. Isoniazid 
resistance showed the strongest association with mortality of the patient (p = 0.005 [OR = 1.78, 
95% CI: 1.18-2.66]) and multidrug resistance was strongly associated with patient mortality in all 
8 patients infected with MDR TB (p < 0.0001 [OR = 5.21, 95% CI: 2.38-11.42]). These results 
show that drug resistance status of the strain, host and strain genotypes and patient HIV status are 
all important determinants of patient survival and thus must be considered during treatment 
administration.   
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Scope of the Thesis 
The research presented in this thesis investigates the role of genetic variants of differing frequency 
in the susceptibility to TBM in the South African Coloured (SAC) population. This was done using 
both exome sequencing gene-set based association analyses and SNP genotyping array 
technologies to conduct a genome-wide association study (GWAS). In light of this, we hypothesise 
that multiple common variants of moderate effect size are more likely to influence TBM 
susceptibility than rare variants of large effect. 
The SAC are a 5-way admixed population with ancestral contributions from African, European 
and Asian population groups. An overview of the population structure, the prevalence of TBM in 
the population and the number of participants used per study subsection is presented (Chapter 2).  
The aim of whole exome sequencing (WES) experiments is to study only SNPs in protein coding 
regions of the genome, because these may alter protein function. An exome sequencing study of 
10 cases and 10 controls is described with the resultant sequence data analysed using Sequence 
Kernel Association Test (SKAT) gene-set association tests. Two SKAT tests are described, firstly 
using only SNPs of rare to low frequency and secondly assessing the cumulative effect of both 
common and rare SNPs on TBM susceptibility in the SAC (Chapter 3).  
Assessment of common SNPs in the SAC population was done using a second technology, that of 
the Illumina® Multi-Ethnic Genotyping Array (MEGA) for SNP genotyping. SNP selection 
included functionally relevant SNPs and those previously associated with asthma and other 
respiratory diseases such as TB. Amongst these, select genome-wide tag SNPs were selected to 
increase the power for detection of association using exome sequencing content from over 12 000 
individuals. Our first GWAS included 114 TBM patients and 395 healthy controls to assess the 
role of common SNPs in TBM susceptibility. A second GWAS was done with 114 TBM cases and 
382 pTB cases to determine SNPs that increase susceptibility to dissemination of M. tb to the CNS 
for TBM development (Chapter 4).  
Concluding remarks on the results of the study as a whole are presented in Chapter 5. Limitations 
of the study design are discussed and their possible effects discussed. Candidate genes found 
during exome sequencing and the GWAS highlight the need for further investigation. 
Stellenbosch University  https://scholar.sun.ac.za
 







Chapter 2: Contents 
Chapter 2: Study Population and Participants .............................................................................. 28 
2.1 Study Participants ........................................................................................................... 28 
2.1.1 Ethics approval........................................................................................................ 28 
2.1.2 TBM study participants........................................................................................... 28 
2.1.3 Pulmonary TB patients ........................................................................................... 28 
2.1.4 Healthy control individuals ..................................................................................... 29 









Stellenbosch University  https://scholar.sun.ac.za
Chapter 2: Study Population 
28 | P a g e  
 
Chapter 2: Study Population and Participants 
2.1 Study Participants 
The Western Cape Province has one of the highest TB incidence rates in the world, approximately 
1033 per 100 000, as measured in 2011 [152]. This province also has one of the highest TBM 
incidence rates in the world, 31.5 per 100 000 in children younger than one year, as measured in 
2006 [11]. The major ethnic group in the Western Cape is the admixed South African Coloured 
(SAC) population (48.8%) [153]. Population genetics analyses have revealed a complex five-way 
admixture for the SAC which includes contributions from European, East Asian, South Asian, 
Bantu-speaking African and KhoeSan populations [154].  To account for the possible effects of 
multiple contributing ancestral populations, it is necessary to correct for population stratification 
in our genetic analyses [155]. 
2.1.1 Ethics approval 
This study was approved by the Health Research Ethics committee of Stellenbosch University 
(project numbers 95/072 and N09/07/185). Written informed consent was obtained from all adult 
study participants and legal guardians. Assent was obtained from minor children.  
2.1.2 TBM study participants 
HIV-negative TBM patient samples were collected and stored as part of an ongoing recruitment 
in collaboration with Paediatrics and Child Health, Tygerberg Children’s Hospital, Cape Town, 
South Africa since 1991. Approximately 3 TBM cases are diagnosed per month. Diagnosis is 
classified into two sub-categories “Proven TBM” and “Probable TBM”. Proven TBM cases were 
diagnosed when M.tb is able to be isolated from the CSF. Probable TBM cases are cases that 
exhibit clinical evidence of meningitis with concurrent hallmark CSF findings or imaging 
evidence, in addition most likely alternative diagnoses were able to be ruled out. Population and 
language information was collected for each individual in the study. The TBM samples used in 
this study included 96 SAC and 30 Xhosa individuals. Sample characteristics concerning sex, age 
and ancestry proportions are shown in Table 2.1. 
2.1.3 Pulmonary TB patients 
Pulmonary TB patients used in the study self-identified as part of the SAC population, and were 
recruited from two metropolitan areas of Cape Town. These areas were selected due to the high 
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TB incidence (1340 per 100 000) and low HIV prevalence (approximately 2% of the population) 
at the time of sampling [156, 157]. All study participants were HIV negative and unrelated. 
Diagnosis of pTB was determined through bacteriological confirmation using either smear and/or 
culture methods for positivity. 
2.1.4 Healthy control individuals 
Control samples were collected from the same metropolitan areas as the pTB cases and therefore 
share the same environmental and socio-economic circumstances. Controls were over the age of 
18, HIV-negative and unrelated to one another or to the cases. Additionally, control samples were 
defined as individuals who had never had a case of active TB in their lifetime, however, this does 
not exclude the possibility of latent infection. Positive tuberculin skin tests (TST) were observed 
in 80% of children older than 15 years in this population, indicating significant exposure of control 
individuals to M.tb [158]. 
Table 2.1: Sample characteristics of the study including sex, age and ancestry proportions per study arm.  
  Study 
Exome Sequencing GWAS TBM vs. 
Controls 
GWAS TBM vs. pTB 
Cases Number of Cases 10 114 114 
Nr Males (prop) 5 (0.50) 59 (0.52) 59 (0.52) 
Age (mean ± SD) 5.1 ± 3.93 5.24 ± 4.86 5.24 ± 4.86 
African San [IQR] 0.27 [0.24-0.35] 0.29 [0.22-0.38] 0.29 [0.22-0.38] 
African non-San [IQR] 0.42 [0.31-0.74] 0.36 [0.24-0.65] 0.36 [0.24-0.65] 
European [IQR] 0.09 [1x10-5-0.14] 0.04 [1x10-5-0.10] 0.04 [1x10-5-0.10] 
South Asian [IQR] 0.08 [1x10-5-0.14] 0.19 [0.05-0.26] 0.19 [0.05-0.26] 
Controls Number of Controls 10 395 382 
Nr Males (prop) 5 (0.50) 118 (0.30) 212 (0.55) 
Age (mean ± SD) 49.65 ± 12.79 30.88 ± 13.10 36.32 ± 11.04 
African San [IQR] 0.31 [0.27-0.45] 0.25 [0.19-0.34] 0.31 [0.20-0.40] 
African non-San [IQR] 0.20 [0.15-0.24] 0.27 [0.19-0.38] 0.24 [0.15-0.36] 
European [IQR] 0.24 [0.22-0.29] 0.12 [0.05-0.20] 0.17 [0.12-0.22] 
South Asian [IQR] 0.11 [0.08-0.15] 0.25 [0.18-0.31] 0.15 [0.10-0.21] 
IQR = Interquartile range  
SD = Standard deviation  
Prop = Proportion  
GWAS = Genome-Wide Association Study 
To avoid linear dependency in the data, the East Asian component was not added to the model 
P values reflect the significance of the association of each factor with TB, adjusted for the other factors 
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2.1.5 DNA extraction from blood 
DNA was extracted from blood according to the Nucleon BACC Genomic Extraction Kit protocol 
(Illustra, Buckinghamshire, UK). Concentration and purity assessments of DNA were determined 
using the Nanodrop 2000c and Nanodrop 2000/2000c software (ThermoFisher Scientific 
Waltham, MA, USA).  
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Chapter 3: Exome Sequencing  
3.1 Introduction 
The human genome has approximately 3 billion nucleotides of which protein coding exonic 
regions constitute an estimated 1.22% [159]. The aim of WES experiments is to sequence only 
protein coding regions of the genome. The hypothesis behind this study design is that SNPs in 
exonic regions directly affect produced proteins and thereby its function. The approximately 20 
000 genes in the human genome are made up of 233 785 exons which are targeted during library 
preparation [160]. The exome therefore represents a subset of the genome in which SNPs are more 
likely to exert a direct impact on protein function, especially where non-synonymous amino acid 
changes are induced.   
Preparation for WES involves the construction of a sequencing library with fragmented genomic 
deoxyribonucleic acid (DNA) as input. DNA shearing is random but size-specific (~150 base-pairs 
(bp)) to limit off-target reads as most exons are less than 200bp long (Figure 7) [160]. Sequence-
specific adaptors are ligated to each fragment and is followed by library enrichment and capture 
of exonic portions of the genome [161]. This process requires the hybridisation of designed 
sequence-specific exonic probes to the fragmented DNA. Hybridised complexes of exonic portions 
are then isolated through biotin-streptavidin based capture isolation in the presence of a magnetic 
field. The target DNA is then eluted and amplified post-hybrid-selection and sequenced (Figure 
3.1).  
Despite exome sequencing being a sensitive tool, its application to complex disorders benefits 
from targeted study design strategies. Such designs involve sampling of rare or extreme 
phenotypes of disease for sequencing. This approach has been validated through the discovery of 
novel candidate genes for paediatric inflammatory bowel disease and chronic Pseudomonas 
aeruginosa infection in patients with cystic fibrosis [162–164]. Improvements in WES 
technologies to improve data accuracy and library preparation are ongoing, but a large hurdle in 
terms of library probe design remains the identification of protein-coding exonic regions in the 
genome. Initial probe designs centred on high confidence regions but as the capacity and accuracy 
of the technology increased so has the number of targeted regions included in contemporary library 
preparation kits [165].   
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WES has been previously demonstrated to be a powerful tool in rare disease research through the 
discovery of a novel gene implicated in a rare Mendelian disease, Miller syndrome [159]. WES 
allows for the identification and characterisation of rare SNPs in the comparatively low sample 
sizes found in rare disease research, and provides a smaller, focussed dataset for analysis. WES 
provides a viable research tool for investigation of rare to low frequency SNPs which are thought 
to be of large effect size and cumulatively contribute to the overall disease phenotype and rare 















3.1.1 Sequence Kernel Association Test (SKAT) 
GWAS investigate common variants (frequencies > 1% in the study population) that often display 
relatively small effect sizes with regards to disease susceptibility [166]. Findings from GWAS 
have not been able to explain the heritability of TB disease. Additionally, GWAS to date have 
Figure 3.1: Overview of exonic sequence capture through hybridisation with 
biotinylated streptavidin beads. This is done during library preparation for exome 
sequencing. Red bars = Intronic genome portions, Blue bars = Exonic regions 
which are captured by probes (striped bars). Adapted from [161] 
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displayed a very low level of replication across population groups. This lack of reproducibility 
may be attributed to differences in allele frequencies between population groups [167]. Research 
focus has shifted towards investigations of rare SNPs of predicted large effect size, with 
frequencies in the range of 1-5% (low) and below 1% (rare) [168–172]. Rare variants are relatively 
uncharacterised in the context of GWAS, as many are removed from analyses by minor allele 
frequency quality control (QC) measures. GWASs also require large sample sizes for adequate 
power to detect associations [173]. Rare SNPs may play a role in TBM susceptibility, especially 
given the incidence of TBM disease in the population, which may point to SNPs of low frequency 
being causal. 
The cumulative effect of rare SNPs in a single gene or across functionally similar genes in a 
pathway may impact upon the susceptibility of individuals to disease. Given recent population 
expansions it is plausible that large numbers of functionally relevant rare SNPs account for a 
proportion of phenotypic variation in the population [174]. Evidence is provided by disorders that 
are predominately monogenic, where the additive effects of rare SNPs in the same gene were 
associated with the disease [175, 176].  
Rare SNP association analyses face a major hurdle during study design, namely the large sample 
sizes required to detect the subtle variations in frequency between case-control groupings. To 
circumvent this issue when testing SNPs individually, studies have ‘collapsed’ SNPs into genetic 
regions and testing these regions for frequency differences [177]. Using this method, the multiple 
testing burden is reduced for these tests as independent tests are not performed on a per-SNP basis. 
Various algorithms have been developed to accomplish a gene-set based analysis such as Sequence 
Kernel Association Test (SKAT), Cohort Allelic Sums Test (CAST) and the C-alpha test [177–
179]. CAST is defined as a burden test, a cumulative association test for rare SNPs that tests the 
association of overall SNP burden in gene regions with disease susceptibility. Burden tests collapse 
genotypic information for groupings of rare SNPs into singular genetic scores. The genetic score 
calculated is then tested for association with the trait of interest. These tests are powerful when the 
majority of SNPs are causal and exert effects in the same direction. The disadvantage is their lack 
of power when effects are balanced in directionality or the proportion of causal SNPs is low [171]. 
SKAT and the C-alpha test on the other hand are termed variance-component tests, which test the 
variance of genetic effects between regions. This increases the power in studies where SNP 
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directionality is balanced and a small proportion of SNPs are likely to be causal, but power is 
decreased when the majority of the SNPs exert effects in the same direction [171].  
In order to optimise the power achievable by studies investigating rare SNPs, SKAT-O was 
developed: an optimised version of SKAT [180]. SKAT-O is more tolerant of the proportion of 
SNPs that are causal in datasets and also to bi-directionality of SNPs. This is achieved through the 
combination of both the variance-component testing of SKAT and burden tests to create an 
optimised test which is tested across a series of values for ρ to select the ideal test per gene-set. 
The optimised nature of the tests makes them an attractive option as little is known of the 
underlying genetic architecture prior to testing. 
Sequencing-based studies represent a unique opportunity to assess the relative contribution of both 
common and rare SNPs simultaneously. Previous gene-set based association tests, including 
SKAT tests, have been able to assess the cumulative effects of SNPs of varying frequency. The 
focus of these tests was biased to up-weight the effects of rare SNPs and consequently down-
weight those of common SNPs [181]. In doing so, considerable losses in power were noted when 
common and rare SNPs in the same region cumulatively influenced susceptibility to certain traits. 
Considering that the contribution of rare and common SNPs to disease risk is not known prior to 
testing for any possible trait locus, it is not surprising that power losses were observed. It is likely 
that SNPs of varying frequency cumulatively contribute towards gene loci conferring susceptibility 
to a particular trait. For this reason, omnibus testing procedures such as SKAT Common Rare 
enable the simultaneous assessment of both common and rare SNPs to determine their contribution 
to overall disease susceptibility at loci of interest. SKAT Common Rare testing involves the 
partitioning of SNPs into frequency-based bins and then testing bins separately to determine their 
relative association in loci of interest. These scores are then combined across genetic loci using a 
multivariate Hotelling’s T-Square statistic. Through this combination method, an overview of the 
cumulative effects of SNPs of varying frequency in genetic loci can be obtained. This testing 
procedure is therefore attractive for exploration into disease pathogenesis studies with the aim of 
identifying candidate genes for future study.  
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3.1.2 Aims  
1. To exome sequence 20 individuals, 10 TBM cases and 10 healthy controls, from the SAC 
population to discover novel SNPs.  
2. To determine if rare SNPs grouped into gene-sets are associated with TBM using the 
SKAT-O test and thereby identify candidate genes for future study. 
3. To assess the cumulative effect of both common and rare SNPs on TBM susceptibility 
using the SKAT Common Rare test and thereby identify candidate genes for future study. 
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3.2 Materials and Methods  
3.2.1 Sample selection for exome sequencing 
Sample selection for exome sequencing involved the selection of 20 unrelated individuals, 10 
TBM cases and 10 healthy controls. Cases and controls were sex matched (Table 2.1). Criteria for 
selection included DNA concentration (>200ng/μl) and quality metrics (260/230 ratio ≤ 2 and 
260/280 ≥ 1.7) as determined by Nanodrop, a nucleic acid quantitation method requiring micro-
volumes of sample. Age selection criteria introduced a bias as patient samples were much younger 
than controls due to the age of onset of the disease. Control samples were selected for older age as 
the risk of TBM development decreases as age increases. Samples were diluted to 200ng/μl in 30µl 
Tris-EDTA and stored in Eppendorf® Safe Lock Tubes (Eppendorf AG, Hamburg, Germany) and 
stored at 4°C during transport. Samples were randomised by sex and disease affection status during 
sequencing to avoid batch effects.  
 
3.2.2 Library preparation parameters 
The input genomic DNA was sonicated to randomly fragment the DNA to a size of 150bp [182]. 
Sonicated DNA quality and size assessment was done using the Agilent Bioanalyser 2100 and 
DNA 1000 chip and reagent kit (Agilent Technologies Santa Clara, CA, USA). Targeted 
enrichment for exonic sites was done using the Nextera XT® enrichment kit (Illumina San Diego, 
CA, USA) which targeted >20 000 genes between 40 to 60x read depth. Library preparation for 
the Illumina Nextera XT® library (Illumina San Diego, CA, USA) used 6µg of DNA and was 
performed according to manufacturer’s specifications. Paired-end sequencing was performed on 
the Illumina® HiSeq 2500 (San Diego, CA, USA) at Christian-Albrechts University of Kiel (CAU 
sequencing Kiel, Germany).  
 
3.2.3 Data pre-processing and QC 
Sequencing data was received from the CAU sequencing facility in .fastq format. Reads were 
mapped to hg19 of the human genome downloaded from the UCSC genome browser [183]. The 
FASTA formatted hg19 reference was indexed prior to mapping using the Burrows-Wheeler 
Aligner (BWA) [184]. Indexing of the reference genome allowed for alignment of forward and 
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reverse .fastq reads to the hg19 reference using BWA-mem. Aligned forward and reverse reads 
were then combined into a .sam file, sorted by chromosomal mapping coordinates. The .sam file 
was compressed into a .bam file which was indexed during the process.  
In order to obtain a graphical overview of the data, Integrative Genomics Viewer (IGV) was used 
to view the sorted and indexed .bam file [185]. Using IGV, read mapping quality was assessed 
along with other metrics such as coverage and read depth. Following graphical read quality 
assessment, duplicates were marked using picard-tools (Broad Institute, 
http://picard.sourceforge.net/) and removed to mitigate the effects of polymerase chain reaction 
(PCR) amplification bias [186]. Mapping statistics such as quality score distributions were 
assessed using bamtools and picard-tools [187]. To assess a panel of QC metrics including 
sequence quality, GC content, adapter content and overrepresented sequences, FastQC [188] was 
run on the .bam file thereby removing adapter sequences.  
 
3.2.4 SNP filtration and prioritisation 
Next generation sequencing (NGS) technologies involve the synthesis of short reads of 
approximately 150 base pairs (bp) with repeated sequencing of regions of interest, resulting in 
multiple sequencing reads of each position [189]. NGS technologies display a higher error rate 
than Sanger sequencing, necessitating multiple reads for each position in the exome to ensure data 
confidence. The exome sequencing portion of the study aimed to assess the role of low frequency 
SNPs in association with TBM susceptibility. Rare SNPs are defined as those below a minor allele 
frequency (MAF) cut-off of 0.01 in the population [190]. Filtration methods were aimed at rare 
variant prioritisation. A single .vcf (variant call format) file contained all called SNPs for all 
samples. Annotation for frequency information and SNP-specific gene regions amongst other 
functional annotations were added using a web version of Annovar (wAnnovar) [191]. SNP 
information for 107 554 SNPs across the 20 sampled individuals were annotated. An overview of 
SNP prioritisation procedures is summarised in Figure 3.2  
The annotated vcf file was filtered to prioritise rare SNPs with a MAF of 0.01 and below. This 
filtration was primarily based upon the annotated MAF provided by the 1000 genomes project 
[192]. Second tier MAF filtration was performed using annotations from the Exome Sequencing 
Project (ESP6500si) which consists of over 6 000 healthy individuals and study participants with 
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several diseases from different populations [193]. Final MAF filtration was done using frequency 
information from the Exome Aggregation Consortium (ExAC) [194]. Based on the criteria 
mentioned above, MAF filtration removed 17 836 SNPs from the dataset. Further filtration for 
retention of non-synonymous variants was done based on the premise that SNPs which change 
amino acid sequence will be more likely to affect protein function [195]. Frameshift SNPs were 
retained as these affect codon usage and may disrupt protein structure and function. SNPs that 
induced stop codon gains or losses, splice-site SNPs and insertions and deletions were retained 
during filtration, during which 53 419 SNPs were removed (Figure 3.2).  
Conserved sequence sites provide a useful resource for the investigation of SNPs, as evolutionarily 
conserved sites are most likely to be functionally relevant [195]. Less conserved sites in the 
genome tend to be more polymorphic and SNPs in these regions are more likely to be tolerated in 
terms of retaining protein structure and function compared to those in evolutionarily conserved 
regions. As conserved sites are less polymorphic, variants in these regions are likely to be of low 
frequency and therefore rare in the population. The combination of SNP frequency and the highly 
conserved nature of the SNP’s location point to increased effect size [196]. Therefore, filtration 
for the retention of conserved sites was performed based on PhyloP [197] and GERP++ scores 
[198], both measures of conservation . SNPs with negative scores (n = 19 108 SNPs) from both 
conservation annotators were removed.  
The chromosome numbers and related base-pair positions specific for each SNP in the filtered and 
annotated vcf were used as a reference for extraction of SNPs of interest from the original vcf file 
using vcftools 0.1.12b [199]. The output was converted to PLINK format using vcftools. PLINK 
v1.07 was used to convert the resultant map/ped format files into binary bed/bim/fam formats 
[200].  
 
3.2.5 SKAT-O Analysis 
SKAT-O analysis was performed to assess the rare-variant burden across all genes containing rare 
SNPs identified using exome sequencing. The Annovar and related PLINK files produced during 
SNP prioritisation were used during creation of the gene-set file. Gene and SNP information were 
extracted by scripts written using the R programming environment (available from www.r-
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project.org) to create a file of SNP IDs grouped into sets according to their corresponding genes 
[201]. Using the R script, duplicate entries and those with missing information were removed.  
Using the genotype-containing .bim file produced during SNP prioritisation in conjunction with 
the gene-set file, the SKAT-specific SSD and SSD.Info files were created through the use of 
incorporated R functions in the SKAT R package [179, 202]. Genotypes from the PLINK-
formatted .bim file were stored in a binary SSD file. Information concerning the number of gene 
sets, the number of SNPs per gene and sample structure of the analysis were stored in the SSD.Info 
file. As a result of filtration and prioritisation procedures, 8 322 genes (SNP sets) and 16 728 SNPs 
were included in the analysis.  
Prior to running SKAT-O, a null model was created to aid in the determination of p-values in the 
analysis. The null model was constructed to incorporate dichotomous phenotypes of TBM patients 
and healthy controls regressed against the study covariates. A single covariate of gender was 
incorporated into the model. During the construction of the null model, only sex was included as 
a covariate, as including any of the others in conjunction with sex resulted in complete separation 
of the data. Complete separation is defined as when the outcome variable separates a single 
predictor variable or a combination of predictor variables completely and correctly allocates all 
observations to their respective groups [203]. Complete separation was likely due to the small 
sample size (n = 20) used in the study and therefore insufficient inter-sample variability was 
observed in the data to allow for the inclusion of further covariates. This could introduce some 
bias as the data is not fully corrected for confounding factors such as ancestral populations or age. 
Age represents a significant stratifying factor in this study, as the patient samples used were very 
young, given the age of onset of TBM, and these were compared to controls who were the oldest 
of all available control samples. This was done as control individuals of older age were less likely 
to develop TBM [204]. To improve the accuracy of p-values estimated under the null model, 10 
000 re-samplings were conducted.  
The SKAT-O test was chosen due to its optimisation parameters to test each gene set’s genotypes 
under the null model. This was shown to be particularly useful in exome sequencing studies due 
to its ability to decrease type I error [202]. The test was conducted under the small-sample size 
kurtosis adjustment, implemented by the SKAT package, as the sample size was under 2 000 
individuals. Optimisation of the test statistics were modulated by the program and tested across 
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the default distribution of ρ (0, 0.12, 0.22, 0.32, 0.42, 0.52, 0.5, and 1) to minimise the p-value 
produced during analysis, which was then used as the test p-value. The results were corrected for 
multiple testing using a Bonferroni-corrected significance cut-off value of 0.05. This cut-off limit 
was chosen because of the small sample size available for the analysis. The SKAT-O procedure 
limited the number of tests conducted due to the collapsing of SNPs into gene regions, thus 
contributing to the retention of study power.  
 
3.2.6 SKAT Common Rare Analysis 
To test the combined effect association of both common and rare SNPs in the analysis, the 
common/rare SNP association test as part of the SKAT R package was used [179, 205]. The SNP 
filtration and prioritisation procedures followed the same procedure as SKAT-O testing, with the 
exception of MAF filtration to retain common SNPs. The SKAT input Set.ID, SSD and gene-set 
files were created as before and all duplicates and missing information was removed. A total of 13 
270 gene-sets with 53 239 SNPs were analysed.  
Null model creation was done as described for SKAT-O testing (Section 3.2.5). 
The test performed made use of the SKAT Common Rare function [181] in the SKAT R package  
[179, 205]. This procedure involved testing common and rare variants in two groups separated 
based on an adaptive MAF value as a function of the total sample size. The p-values of the two 
groups were then combined and weights assigned according to MAF on a per SNP basis. Test 
results were then corrected for multiple testing as in SKAT-O testing at a p-value significance cut-
off of 0.05.     
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Figure 3.2: Overview of the SNP prioritisation procedures followed and association analyses used in the 
exome sequencing arm of the study. SKAT = Sequence Kernel Association Test. 
 
3.2.7 Ingenuity Pathway Analysis (IPA) of SKAT results 
Functional assignment and pathway analysis of the association results was necessary to prioritise 
genes of interest from the SKAT Common-Rare and SKAT-O analyses. Association results were 
VCF Annotation
• Program used - wAnnovar
• 107448 SNPs annotated across 20 
Individuals
MAF Filtration
• Filtered at 0.01 MAF
• Databases for filtration: 1000 
Genomes + ESP6500 + ExAC
• 63828 SNPs removed
SNP type Filtration
• Retained non-synonymous, 
Frameshift-inducing, stop 
gains/losses, splice-site and 
insertions or deletions
• Retention of only the above removed 
20131 SNPs
Conserved Site Filtration
• Filtered on PyloP and GERP++ scores
• Negative scores for SNPs removed
• Removed 6761 SNPs
SKAT-O
• Analysis of 8322 genes (gene-sets) 
• 16728 SNPs across all gene-sets
• 20 Samples - 10 cases, 10 controls
SKAT Common Rare
• No MAF Filtration implicated, all 
other filtrations were identical
• Analysed 13270 gene-sets, containing 
53239 SNPs
• 20 Samples - 10 cases, 10 controls
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filtered for the retention of unadjusted p-values below a threshold of 0.01, this allowed for 
sufficient genes for input. Unadjusted p-values were used in downstream analyses as multiple 
testing correction led to no genes retaining significance. This may be due to the small sample size 
of the study and therefore a lack of power to detect rare associations. As unadjusted p-values were 
used, the likelihood of the included genes being false positives is high.  
Using IPA core analysis, the top hits from both SKAT association tests were assessed 
independently [206]. Assessments conducted include overrepresentation analysis of pathways 
assigned to the input genes, network construction between gene products and genes, functional 
assignment, disease associations and assessment of shared regulatory molecules of the input genes. 
Analysis filtration parameters were defined to draw information from the Ingenuity Knowledge 
Base (genes only). Network construction was not constrained as exploration into related genes was 
desired, thus direct and indirect relationships were used. Filtration parameters for results pertaining 
only to Homo sapiens were applied to exclude any gene functions annotated through homology 
from other species. Additionally, filtration was applied to include only experimentally confirmed 
interactions, thus providing maximum confidence in the results. Using this information, genes of 
interest were prioritised according to pathways and functions thought to be involved in TBM, such 
as BBB regulation and genes displaying immunological functions. Network construction involved 
both direct and indirect interactions to connect input genes to one another. Direct interactions 
biased construction towards protein-protein binding of two input gene products, whereas indirect 
interactions allowed for the connection of input genes that function in the same pathway but do 
not necessarily interact with each other.   
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3.3 Results 
The depth of the exome sequencing obtained in this study ranged from 35x to 82x. The mean depth 
across all 20 individuals was 52x, where coverage between 40x - 60x is generally considered 
adequate for exome sequencing [207]. A total of 107 448 SNPs were called across the 20 study 
individuals. SNP prioritisation for the SKAT-O analysis removed 63 828 SNPs that were above a 
MAF of 1%. An additional 20 131 SNPs were removed during filtration for the inclusion of non-
synonymous and frameshift inducing SNPs, stop gains/losses, splice-site SNPs and insertions and 
deletions. A further 6 761 SNPs were removed as a result of their conservation score, leaving a 
total of 16 728 SNPs for SKAT-O analysis. The SKAT Common Rare prioritisation removed 35 
589 SNPs to prioritise non-synonymous and frameshift inducing SNPs, as previously mentioned. 
A further 18 620 were removed based upon their conservation score, leaving a total of 53 239 
SNPs for SKAT Common Rare analysis. 
 
3.3.1 SKAT-O 
Following SNP prioritisation, a total of 17 191 SNPs were available for analysis. Following 
removal of SNPs with overlapping base-pair positions, SKAT-O analysis was performed on 8 322 
gene-sets containing 16 728 SNPs using a dichotomous phenotype of patients with TBM compared 
to healthy controls. None of the gene-sets were found to be associated after correcting for multiple 
testing using a Bonferroni significance level of p = 0.05. The gene-set with the lowest p-value was 
that of Zinc Finger Homeobox-3 (ZFHX3), punadjusted = 4.63x10
-4. See Appendix 1 for gene-sets 
with punadj < 0.01.  
 
3.3.2 SKAT Common Rare 
SKAT Common Rare analysis testing was done to include both common and rare SNPs in our 
analysis and weighted as described in Chapter 2. This allowed for the inclusion of more gene-sets 
and SNPs, with 13 270 gene-sets and 53 239 SNPs analysed. A single significant association was 
identified by comparing TBM cases and controls and after correcting for multiple testing. The 
Centriolar Coiled-Coil Protein 110kDa (CCP110) gene was found to be associated with TBM (p 
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= 5.89x10-6) after correcting for multiple testing, with the combined effects of 1 rare SNP and 2 
common SNPs contributing to the association. See Appendix 2 for gene-sets with punadj = 0.01.  
 
3.3.3 Ingenuity Pathway Analysis® (IPA) 
Functional pathway analysis allows for the interpretation of association study data results in a 
biological context. It is also useful in hypothesis generation and exploratory analysis of selected 
genes. This will allow future studies to target genes and pathways of interest rather than 
approaching the disease from a genome-wide context which proves to be less economical. IPA 
analysis was performed to explore the pathways affected and the associated functional annotations 
of each gene of interest from both SKAT analyses. 
 
3.3.3.1 SKAT-O 
A p-value cut-off of p < 0.01 was used to identify top hits for exploratory analysis using IPA core 
[206]. Pathway over-representation in the top hits of an association analysis can point towards the 
defective function of a particular pathway and can indicate possible involvement in disease 
pathogenesis. IPA provided a measure of overlap between the SKAT top hits and curated canonical 
pathways in the database. In the SKAT-O analysis, the pathways with the greatest proportion of 
overlap with the SKAT top hits are listed in Table 3.1.  
Table 3.1: Highlighted canonical pathways in the SKAT-O analysis. 
Pathway Name  p-value Overlap between 
input and total genes 




regulation network in 
embryonic stem cells 
2.90x10-3 5%, (2/40) RIF1, ZFHX3 
α-tocopherol 
Degradation 
7.98x10-3 25% (1/4) CYP4F2 
Histamine 
Degradation 
2.57x10-2 7.7% (1/13) ALDH3B1 
Oxidative Ethanol 
Degradation III 
2.96x10-2 6.7% (1/15) ALDH3B1 
Fatty Acid α-
oxidation 
3.15x10-2 6.2% (1/16) ALDH3B1 
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Figure 3.3 shows the results for α-tocopherol degradation wherein both the p-value and overlap 
ratio remain significant as both are above the threshold. The -log p-values are calculated based 
upon the role that each gene plays in the pathway. Ratios are determined by the number of 
overlapping genes between the input genes and the total genes in the curated pathway.  This 
pathway had a -log p-value of 2.098 with an overlap ratio of 25% as the input gene, cytochrome 












Genes that perform similar functions may provide insight into functional defects that influence 
TBM susceptibility. These functions may provide novel information into possible susceptibility 
pathways that influence disease pathogenesis due to a lack of redundancy measures in the host. Of 
interest were functional annotations that were thought to play a role in TBM or pTB pathogenesis, 
such as immune regulation, apoptosis or autophagy related gene functions. The top functional 
annotations are shown in Table 3.2. The Polyhomeotic homolog-1 (PHC1) was not considered as 
a viable candidate for further investigation as it functions in transcriptional regulation in embryonic 
stem cells and is associated with their differentiation rather than bacterial clearance [208]. As 
CYP4F2 had been implicated in enriched pathways (Table 3.2) it was interesting that it was also 
implicated in several functional enrichment categories shown in Table 3.2. Investigations into the 
Figure 3.3: Canonical pathways highlighted in IPA analysis. 
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role of the other genes listed in Table 3.2 did not reveal any plausible links with known TBM 
pathogenesis pathways or functions. 
 
Table 3.2: Enrichments for molecular function in the SKAT-O analysis. 
Functional 
Annotation 
p-value range Annotated Genes 
Lipid Metabolism 3.35x10-2 – 2x10-3 CYP4F2, PIGG, GCKR 
Small Molecule 
Biochemistry 
3.35x10-2 – 2x10-3 CYP4F2, ALDH3B1, PIGG, GCKR, 
ITPR3, ESRRA 
Vitamin and Mineral 
Metabolism 
3.15x10-2 – 2x10-3 CYP4F2, ITPR3 





2.77x10-2 – 4x10-3 FARP2, TOPBP1, ESPL1 
 
Physiological system development is crucial to the overall functioning and performance of the 
system as a whole. Defects in system physiology may affect its ability to function as intended and 
the system may be vulnerable to pathogenic invasion. Table 3.3 shows that nervous system 
development was the most significantly affected physiological system when the input genes from 
the SKAT analysis were considered.  
Table 3.3: The development and function of physiological systems most affected by genes highlighted by 
the SKAT-O analysis. 




Embryonic Development 3.15x10-2 – 4.85x10-3 CC2D1A, NOD2 
Hair and Skin 
Development 
9.96x10-3 – 4.85x10-3 CC2D1A, NOD2 
Renal and Urological 
Development 
9.96x10-3 – 5.22x10-3 CC2D1A, NOD2 




The gene implicated in CNS development (FERM, ARH/RhoGEF and Pleckstrin Domain Protein 
2 (FARP2)) was found to be implicated in the control of neurite remodelling in the cerebellum. It 
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is unlikely that FARP2 plays a role in TBM pathogenesis as neurite remodelling is likely to affect 
neural connections and their development [209].  
The gene Nucleotide binding and oligomerisation domain 2 (NOD2) functions in bacterial 
recognition and autophagy, which are both pathways of interest in TBM. Table 3.3 shows that 
NOD2 was highlighted across several developmental processes, but also functions in pathogen 
recognition in the immune system [210].    
 
3.3.3.2 SKAT Common Rare 
SKAT Common Rare was used to assess the cumulative effects of both common and rare SNPs 
with susceptibility to TBM. As in the SKAT-O IPA results, top hits from the SKAT Common Rare 
test (p < 0.01) were analysed using IPA® Core Analysis [206]. Interestingly, CCP110 was not 
identified in any of the associated pathways, suggesting a lack of involvement. Pathways that were 
common to multiple genes in the SKAT Common Rare results are listed in Table 3.4. Significance 
was only retained for S-methyl-5'-thioadenosine Degradation II in terms of both a significant 
proportion of overlap of input genes with the total genes in the curated pathway and -log p-value. 
This is most likely due to the pathway only having a single gene ascribed to it, methylthioadenosine 
phosphorylase (MTAP), thus its inclusion is overrepresented in the analysis due to the lack of other 
contributing genes. 
Table 3.4: Canonical pathways highlighted in IPA analysis. 
Pathway Name p-value Overlap of input 






7.53x10-3 100%, (1/1) MTAP 
Glycine Biosynthesis III 1.50x10-2 50%, (1/2) AGXT2 
Role of Oct4 in Mammalian 
Embryonic Stem Cell 
Pluripotency 
4.51x10-2 4.4 %, (2/45) FAM208A, 
NR5A1 
Phototransduction Pathway 5.65x10-2 3.9 %, (2/51) GNAT2, 
GUCA1C 
FXR/RXR Activation 6.85x10-2 2.4 %, (3/125) APOF, G6PC, 
G6PC3 
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Regulation of genes that function in similar pathways or perform similar functions may involve 
common regulatory proteins such as transcription factors. This may lead to enrichment of the 
dataset in certain regulatory factors. This is an important consideration as the basis for transcription 
factor function relies on the conservation of the recognition motif or sequence of the target protein. 
Modifications to this binding sequence would likely affect transcription factor target affinity and 
binding efficacy, thereby affecting control of the target gene. Several genes were found to be under 
the control of common regulatory elements, listed in Table 3.5. CD44 was found to target 4 genes 
in the input dataset, namely DNA (cytosine-5) methyltransferase 1 (DNMT1), interferon induced 
transmembrane protein 2 (IFITM2), interleukin 1 receptor associated kinase 3 (IRAK3) and 
programmed cell death 4 (PDCD4). Both IFITM2 and IRAK3 play important roles in immune 
signal transduction pathways, whereas DNMT1 functions in the regulation of gene expression and 
PDCD4 is a tumour suppressor gene.   
Table 3.5: Common regulatory elements for the top-hits of SKAT Common/Rare. 







Pathway analysis revealed that the most enriched disease annotation was that of cancer, with a p-
value between 4.7x10-02 – 9.91x10-04, corresponding with 132 genes highlighted in the SKAT 
Common Rare analysis. Disease enrichments for neurological or pulmonary diseases were not 
found in the IPA analysis. Annotations for enriched molecular and cellular functions are shown in 
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Table 3.6: Enrichments for molecular and cellular functions. 
Functional Annotation p-value Top-Hit Genes Associated 
Cellular Movement 4.43x10-2 - 1.68x10-4 A2M, GNRH1, MYO7A 
Cell Morphology 4.43x10-2 - 4.42x10-3 CYFIP1, MACF1, ROR1, 
ZFYVE16 
Cellular Assembly and 
Organisation 
4.43x10-2 - 4.42x10-3 CYFIP1, MACF1, ROR1, 
KRT20, MAP2, PACS2, 
EXO5, ANLN, DDX11, 
ZFYVE16, SPAG16, 
NLGN4X, MYO7A 
Cellular Function and 
Maintenance 
4.43x10-2 - 4.42x10-3 CYFIP1, MACF1, ROR1, 
KRT20, A2M, SPAG16, 
MAP2, NLGN4X, MYO7A 
Cell Cycle 2.98x10-2 - 7.53x10-3 PNTP1, HAVCR1, EXO5, 
CLSPN 
 
Enrichment analysis pertaining to genes functioning in physiological system development 
highlighted genes which function in neurological development as some of the top hits ascribed to 
the input gene list from the association analysis, as shown in Table 3.7.  




p-value Genes ascribed to pathway 




3.71x10-2 - 7.53x10-3 GNRH1, NR5A1, NLGN4X 
Hair and Skin 7.53x10-3 KRT20 
Haematological 
system 






This result was relevant given that hits for the enrichment of genes involved in the proper 
development and functioning of neurological, embryonic, haematological and humoral immune 
response systems were all highlighted. This could point towards defects in the development and 
function of several critical physiological functions forming part of the aetiology of TBM.  
Stellenbosch University  https://scholar.sun.ac.za
Chapter 3: Exome Sequencing 
51 | P a g e  
 
IPA generates networks during core analysis between input genes and populates the relationships 
between input genes with known interactors from the Ingenuity Knowledge Base. Network 
analysis showed that two of the input genes, receptor tyrosine kinase-like orphan receptor 1 
(ROR1) and DNMT1, both regulate cadherin-1 (CDH1), a critical tight junction protein in the BBB 
(Figure 3.4). ROR1 was also identified in a number of functional enrichments (Table 3.6), 
including cell morphology, cellular assembly and organisation and cellular function and 
maintenance. ROR1 has also been shown to regulate other critical tight junction proteins at the 














DNMT1 functions in gene regulation through the process of methylation of CpG sites and is a key 
epigenetic regulator during development. It exerts its methylation activity upon the promoter 
region of CDH1 specifically in order to lower its expression [212].  
Figure 3.4: The relationships between CDH1, ROR1 and DMNT1. ROR1 interacts indirectly through 
other proteins to exact its regulatory function upon CDH1, denoted by the broken line. DNMT1 
interacts with CDH1 in a direct protein-protein interaction, denoted by the solid line. 
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Finally, the top hit genes were analysed for possible involvement in pathways that have been 
previously implicated in TBM or pTB pathogenesis, for example immune system regulation and 
autophagy related processes. As shown in Table 3.8, an additional 12 genes were found that may 
play an important roles in known TBM pathogenesis pathways, but have yet to be investigated in 
the context of this disease.  
Table 3.8: Genes from the SKAT Common/Rare top hits that function in pathways thought to be involved 
in TBM pathogenesis. 
Gene ID Gene Name Function and Pathway 
A2M Alpha 2 Macroglobulin Cytokine transporter, IL-6 
pathway 
ATG10 Autophagy-related 10 Autophagy – 
Autophagosome formation 
C4BPA Complement component 4 
binding protein, alpha 
Regulation of the 
complement system 
CX3CR1 Chemokine (C-X3-C motif) 
receptor 1 
Leukocyte adhesion and 
migration, activation of 
microglia 
IRAK3 Interleukin 1 receptor 
associated kinase 3 
Component of the toll/IL-1 
pathways, negative regulator 
of TLR signalling 
MARCO Macrophage receptor with 
collagenous structure 
Innate immune signalling, 
Recognition receptor 
IFITM2 Interferon induced 
transmembrane protein 2 
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3.4 Discussion 
3.4.1 Exome Sequencing: SKAT-O 
Assessment of the proportion of rare variants was performed using the SKAT-O gene-set 
association test. Results indicted a lack of significant association following adjustment for multiple 
testing correction and using gender as a single covariate.  
Pathway enrichment analyses were done using IPA to determine possible susceptibility pathways 
in which multiple genes may function. In doing so, CYP4F2 (Table 3.2), was highlighted as 
functioning in the α-tocopherol degradation pathway (penrichment = 1x10-3). Further functional 
investigation of CYP4F2 showed involvement in the early stages of leukotriene B4 (LTB4) 
degradation [206, 213, 214]. This is of interest as the leukotriene A4 hydroxylase (LTA4H) locus 
has previously been shown to play a role in in TBM susceptibility due to its effects on TNF-α 
levels [98, 99]. Specifically, the control of TNF-α concentrations was found to differ based on 
genotype. Wild-type homozygotes showed hyper-inflammation due to an excess of LTB4, which 
in turn led to an excessive TNF-α response. The involvement of CYP4F2 in LTB4 regulation is 
mediated by degradation of LTB4 through ω-hydroxylation leading to the attenuation of TNF-α 
signalling thus modulating the inflammatory response along with the LTA4H enzyme [214]. In 
addition, CYP4F2 and CYP4F3 have been shown to metabolise lipoxin A4 (LXA4) and lipoxin B4 
(LXB4), both known anti-inflammatory lipoxins [215]. An excess of LXA4 in particular has been 
shown to result in a hypo-inflammatory phenotype due to its anti-inflammatory actions on TNF-
α. Therefore a contributing factor to this excessive LTB4 and LXA4 could be attributed to non-
synonymous SNPs in CYP4F2 causing a loss of protein function, with rs3952537 predicted to be 
damaging  by SiFT, Polyphen-2 and loss-of-function protein effect predictions as provided by the 
variant effect predictor (VEP) accessed through Ensembl [216]. In fact two CYP4F2 SNPs, rs1272 
and rs3093158, have been implicated in Crohn’s Disease susceptibility in Canadian children [217]. 
To fully determine the role that CYP4F2 may play in the regulation of TNF-α concentration, the 
interplay between these molecules needs to be functionally assessed in vivo, particularly in TBM 
patients.  
Pathways highlighted by IPA may provide insight into TBM pathogenesis. These results can 
therefore be used to generate hypotheses. This approach aids in focussing future studies on 
candidate genes which function in relevant disease pathways rather than viewing the data from a 
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genome-wide context. Table 3.3 highlights genes from the IPA analysis that were of interest 
considering their roles in immune system regulation, autophagy and CNS development. Nucleotide 
binding and oligomerisation domain (NOD2) formerly known as CARD15, was found to be 
important in the development of three independent physiological systems including embryonic, 
hair and skin and renal developmental processes. NOD2, however, is of greatest interest for its role 
in innate immunity and is expressed on the surface of astrocytes and microglia in the CNS and 
functions as a recognition receptor for S. pneumoniae LPS derived muramyl dipeptide [218]. 
Additionally, it has been implicated in the generation of IL-6 and TNF-α pro-inflammatory 
cytokines through the stimulation of NFκB towards other forms of bacterial meningitis caused by 
N. meningitidis and B. bergdorferi [210]. Through the use of two murine models of NOD2+/+ and 
NOD2-/-, acute CNS inflammation was demonstrated with increased levels of CCL3, TNF-α and 
decreased levels of anti-inflammatory IL-10 in NOD2+/+ mice [218]. This demonstrates a plausible 
role for NOD2 in the generation of a detrimental inflammatory response as observed in TBM. 
NOD2 may represent a viable candidate gene for investigation in the context of TBM considering 
that the recognition of peptidoglycan derivatives would also be possible given the presence of 
peptidoglycan in the cell walls of M.tb [219]. Genotypic association studies in our study population 
of the p.Arg702Trp, p.Gly908Arg and p.Phe1007Ser polymorphisms which have been previously 
associated with Crohn’s disease, showed a lack of association with pTB susceptibility [220]. These 
associations, however, have not been examined in the context of TBM patients to determine 
susceptibility.  
The lack of association found in the SKAT-O analysis and the lack of representation of the top-hit 
genes in TBM pathogenesis pathways is not surprising when the frequency of the SNPs used is 
considered. Only a small number of SNPs were included in the analysis leading to lowered study 
power to detect associations with any gene. Additionally, due to the rarity of the SNPs, a further 
decrease in power will have been observed as a result of the small sample size of 20 individuals 
investigated. These limitations may have increased the false positive rate of the results found in 
the SKAT-O analysis and thus candidate genes identified should be individually genotyped using 
tag-SNPs in a much larger TBM cohort to glean a better understanding of the role of each candidate 
gene in TBM pathogenesis, assuming that associations are found between individual SNPs and 
TBM susceptibility [221].  
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3.4.2 Exome Sequencing: SKAT Common Rare 
In contrast to the lack of significance found in the SKAT-O analysis, the SKAT Common Rare 
analysis found a single gene-set after correction for gender and multiple testing. CCP110 was the 
only significant result (p=5.89x10-6). CCP110 functions in cell-cycle maintenance, centrosomal 
duplication and is a negative regulator of ciliogenesis [222]. Given its functional annotations and 
its role in centrosomal duplication, it seems unlikely that CCP110 will have a direct effect on TBM 
pathogenesis pathways. Considering that proper correction for all covariates was not possible, it is 
plausible that CCP110 is a false positive. CCP110 was also not highlighted in any of the pathways 
or functional annotations during IPA analysis. However, since none of the covariates, besides age, 
were found to be significantly different between the case and control groups it is also possible that 
CCP110 has an unknown function that may play a role in TBM.   
The proper development of physiological systems such as the nervous system is critical especially 
when the age of onset of TBM is considered [223]. The IPA analysis of the SKAT Common Rare 
top associations revealed 6 genes known to function in the development of the nervous system. 
This is critical in TBM pathogenesis as incomplete or poor development of protection mechanisms 
in crucial nervous system barriers such as the BBB, may expose the nervous system to pathogenic 
attack. One of these genes, alpha 2 macroglobulin (A2M), functions as a protease inhibitor for all 
four classes of proteases and is also a cytokine transporter for TNF-α, IL-6 and IL-1β amongst 
others [224]. A2M is regulated by IL-6, a prominent cytokine in TB pathogenesis, through signal 
transduction using STAT3 [225]. A2M along with IL-6 and C-Reactive-Protein (CRP) levels in the 
CSF have been shown to be indicative of blood-cerebrospinal fluid barrier (BCB) damage in 
bacterial meningitis as part of the acute phase reaction [226]. The acute phase reaction involves 
the rapid activation of the inflammatory response by both the innate and adaptive immune systems 
to pathogenic challenge [227]. A2M has been reported as a possible biomarker for disease 
progression in both pTB and all forms of EPTB largely due to its role in IL-6 transport [228, 229]. 
Its inhibitory properties mediated by protease activities have shown a distinct role in the regulation 
of matrix metalloproteases (MMPs, specifically), most notably MMP-9 and MMP-2, in addition to 
which it regulates transforming growth factor beta (TGF-β1) [230, 231]. Notably, MMP 
dysregulation may contribute greatly towards nervous system damage observed in TBM as MMPs 
damage BBB components and are a leading cause of intracranial haemorrhage [231, 232]. TGF-β 
has been implicated in other forms of bacterial meningitis as a suppressor of polymorphonuclear 
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leukocytes which release reactive oxygen species and IL-1β amongst others [233]. These functions 
do assist in bacterial clearance, but also contribute to the inflammatory damage to the nervous 
system. TGF-β deletions were found to increase the recruitment of polymorphonuclear leukocytes 
to the CNS and ultimately enhanced bacterial clearance and significantly decreased vasculitis. In 
light of this, it could be suggested that A2M-mediated clearance of TGF-β could induce similar 
effects on bacterial clearance and the occurrence of vasculitis with concurrent increases in 
inflammation. Due to its roles in the degradation and transport of MMP, TGF-β and IL-6, A2M is 
a good candidate gene for future studies as a potential biomarker and for functional studies in the 
context of TBM.  
A second gene highlighted in the category of nervous system function and development was 
CX3CR1. Its ligand, CX3CL1 or Fractalkine, functions in leukocyte adhesion to endothelial cells 
and the recruitment of T and B lymphocytes [234, 235]. CX3CR1 encodes its receptor and plays a 
crucial role in signal transduction leading to the activation of microglia [236]. Its developmental 
functions may be restricted to microglial activation in terms of neuronal pruning during the basal 
development of the brain, but it has also been implicated in angiogenesis [236]. Under pathogenic 
challenge, microglia are activated through CX3CL1-CX3CR1 binding and production of TNF-α, 
IL-1β and IL-6 is induced [237]. Expression of these cytokines leads to an inflammatory response 
which has been shown to induce ischemic injury if cytokine expression is not ablated [237]. Studies 
involving CX3CR1-/- mice found that knockout mice exhibited reduced immune-cell recruitment 
to the site of infection, however, mycobacterial clearance was not significantly affected [238]. This 
suggests the presence of redundancy measures with regards to mycobacterial clearance, where 
ablation of CX3CR1 expression may influence the amount of ischemic injury observed in TBM 
patients, but this requires further investigation. CX3CR1 protein expression is upregulated in the 
presence of TGF-β leading to the inhibition of fractalkine-mediated signalling and a resultant 
decrease in microglial activation [239]. Through this mechanism, the microglial activation 
response towards M.tb may be affected, especially when the number of immune-related genes 
regulated by TGF-β is considered. Given the roles CX3CR1 plays in microglial activation and 
inflammatory responses, further functional studies should be conducted to further our 
understanding of CX3CR1 involvement in a TBM setting. 
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Additional genes ascribed to nervous system development functions include: CYFIP1, GNRH1, 
MACF1 and NLGN4X. These 4 genes display strictly developmental functions with particular 
focus on neuronal body or axonal extension. Cytoplasmic FMR1-interacting protein 1 (CYFIP1) 
is a repressor of fragile X mental retardation 1 (FMR1), which functions in female reproduction. 
Additionally, CYFIP1 functions in axonal outgrowth [240]. Gonadotropin-releasing hormone-1 
(GNRH1) displays critical functionality in reproduction through the release of gonadotropins. It is 
also responsible for the migration of GNRH1-expressing neurons from the developing nasal 
passages to the forebrain during early development [241]. Neuroligin 4, X-linked (NLGN4X) is a 
neuronal cell surface protein that binds specifically to presynaptic neurexins to induce synaptic 
remodelling during brain development [242]. Microtubule-actin crosslinking factor 1 (MACF1) 
enables the interaction between actin and microtubule subunits at the cell periphery and assists in 
neuronal development as a positive regulator of the Wnt pathway which is responsible for tissue 
generation and axonal guidance [243]. These genes may not necessarily play a direct role in TBM 
pathogenesis, but their developmental role leads to the question of whether a developmental aspect 
could contribute to TBM pathogenesis through the introduction of vulnerable tissues. These tissues 
may display “leaky” characteristics making them vulnerable to bacterial migration allowing easier 
migration into the CNS in carriers with SNPs in the genes listed above.  
Investigation of the haematological system development functional annotation, highlighted both 
CX3CR1 and A2M, which have been discussed above, as well as macrophage receptor with 
collagenous structure (MARCO). MARCO is a member of the class A scavenger receptors and 
functions in the recognition of mycobacterial cell surface trehalose dimycolate (TDM) moieties 
through an extracellular C-terminal, scavenger receptor cysteine-rich domain (SRCR) [244]. This 
recognition is mediated through interactions with both TLR2 and CD14 and induces NF-κB 
activation and the production of TNF-α, IL-6 and IL-12 [245]. As a result of the recognition of 
TDM, marked increases in the cell surface expression of MARCO have been observed in response 
to BCG infection in mice [246]. SNPs have also been investigated in MARCO for association with 
susceptibility to pTB in both the Chinese Han and the Gambian populations [247, 248]. A SNP, 
rs17009726, was associated with increased susceptibility to pTB (p = 9.27x10-5 [OR = 1.65, 95% 
CI: 1.35-2.05]) [247]. A haplotype block GC containing rs17009726, p = 0.0001 was associated 
with increased susceptibility to pTB. A second haplotype block TGCC including rs17795618, 
rs1371562, rs6761637 and rs2011839, was also associated with increased susceptibility to pTB 
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with p = 0.029 [247]. Three SNPs: rs4491733, rs12998782 and rs13389814 were found to be 
associated with increased susceptibility to pTB in the Gambian population [248]. Additionally a 
single SNP was found to increase resistance to pTB, rs7559955[248]. MARCO cell surface 
receptors expressed on glial cells also have a proven role in meningitis defence which has been 
investigated in the context of S. pneumoniae and N. meningitidis, the two most common causes of 
bacterial meningitis [245]. A 5-fold (±0.8-fold) increase in MARCO protein expression was 
observed in astrocytes following a 12 hour infection with N. meningitidis [245]. Cytokine 
production was also shown to increase as measured by IL-1β production. Increased cell surface 
expression and cytokine production was significant for both astrocytes and meningeal cells [245]. 
Although MARCO has proven action as a recognition receptor for M.tb specific surface moieties 
in pTB and recognition of other forms of bacterial meningitis, no study has investigated MARCO 
polymorphisms in a TBM setting. Considering its involvement in both disease types is a necessity 
to better understand the pathogenesis of TBM.  
The construction of networks between input genes provided an overview of the interactions 
between the genes of interest and gives a view of the regulatory effects of each interaction. The 
analysis of one of these networks (Figure 3.4) highlighted the relationship between ROR1 and 
CDH1. ROR1 is a modulator of neurite growth in nervous system development and a mediator of 
endothelial-mesenchymal transition (EMT) during development [211, 249]. EMT is the process 
during which endothelial cells undergo phenotypic transition. This is initiated through the loss of 
classic endothelial cell markers, one of these being vascular endothelial cadherin (CDH5). These 
transitioning cells display a mesenchymal phenotype and begin to express cell products specific to 
mesenchymal cells. This transition enables increased motility and migration into neighbouring 
tissues and this process can be induced through TGF-β [250]. ROR1 was found to regulate this 
process and inhibitory studies have shown a concurrent decrease in the expression of proteins 
linked with EMT such as vimentin, SNAIL-1 and -2 and zinc finger E-box binding homeobox 1 
(ZEB1). The expression of CDH1 was increased as was the expression of several tight junction 
proteins [211]. This shows that ROR1 plays a regulatory role in the expression of tight junction 
proteins during embryogenesis, as it is expressed at low levels in adult tissues [251]. The regulation 
of tight junctions is mediated by the Snail-1 and -2 transcription factors as increased signalling 
through the binding of the WNT5A ligand to the ROR1 protein stimulates the production of the 
T-cell Factor (TCF) and lymphoid enhancer factor (LEF) transcription factors which bind to the 
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promoter of SNAI1 [252]. Snail-1 and Slug (SNAI2) have been shown to regulate tight junction 
proteins zona occludens-1 (TJP-1), occludin (OCLN) and VE cadherin (CDH5) in bacterial 
meningitis caused by group B Streptococcus (GBS) [253]. This downregulation induced BBB 
disruption as permeability was increased. This was modelled in zebrafish which exhibited 
significantly increased bacterial loads and mortality compared to non-infected controls [253]. The 
induction of SNAI1 was found to be dependent upon extracellular signal-related kinases 1/2 and 
mitogen activated protein kinase (ERK1/2/MAPK) signalling cascades mediated through the 
recognition of cell wall components by the TLR pathway. This mechanism of SNAI1 BBB 
disruption was further supported through the investigation into the mechanics surrounding an 
observable downregulation of claudins-7 and -10 in both S. pneumoniae and H. influenzae 
infection [254]. Additionally, SNAI1 induction was preceded by MAPK and TGF-β signalling 
pathways which were initially stimulated through TLR pathogen recognition.  
The functional role of ROR1 has yet to be properly elucidated and studies into its functional 
mechanics are sparse. Therefore implicating ROR1 as a candidate gene for future study needs to 
be done with caution as our knowledge of its biological role and our knowledge of biological 
pathways as a whole is largely fragmented. Its ligand wingless homolog 5A (WNT5A), was shown 
to be differentially expressed in a microarray-based assessment of gene expression during M.tb 
infection [255]. Its induction was found to be TLR and NF-κB mediated, a novel pathway that has 
not been previously described, and expression was restricted to antigen-presenting cells such as 
macrophages. Binding of WNT5A to its other receptor frizzled-5 (FZD5) led to an increase in the 
IL-12 and IFN-γ production of peripheral-blood mononuclear cells following stimulation [255, 
256]. Investigations into the concurrent activation of both TNF-α and WNT5A have led to the 
description of two subsets of cytokines that only partially overlap but are regulated by both in 
tandem, showing that WNT5A cytokine production is independent of TNF-α induction [255, 257]. 
WNT5A signalling has been implicated in the inflammatory phenotypes observed in other diseases 
such as psoriasis, metabolic dysfunction during obesity, sepsis and rheumatoid arthritis [257–263]. 
WNT5A expression was also observed in granulomas taken from M.tb patients [255]. WNT5A SNPs 
have been investigated for association with pTB and no significant associations were found [264]. 
These results, however, do not mean that SNPs in WNT5A are not associated with TBM. Given 
the upregulation of expression of WNT5A in macrophages and the consequent induction of pro-
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inflammatory cytokines, studies into ROR1 expression profiles in macrophages in response to 
mycobacteria should be assessed.  
A single SNP, rs7527017, was analysed in ROR1 and induces a non-synonymous amino acid 
change from a threonine to either a lysine or a methionine, depending on the transcript isoform of 
ROR1. rs7527017 has a MAF of 0.07695 (p.Thr518Met) in the African population according to 
the Exome Aggregation Consortium (ExAC) [194]. The threonine to lysine substitution was not 
observed in the African population. When analysed using VEP SNP effect prediction software, 
PolyPhen [265] and SiFT [266] effect prediction tools estimated damaging effects for the threonine 
to methionine substitution of 0.04 and 0.63, respectively. The threonine to methionine substitution 
induced by rs7527017 creates a new start codon in the middle of the transcript. Functional 
prediction using the loss-of-function tool (LoFtool) as a VEP plugin, showed a damaging score of 
0.189, implying that the introduction of a new start codon would render both transcripts non-
functional [216]. To date this SNP has only been studied in B-cell chronic lymphocytic leukaemia 
using a very small sample size of 15 individuals and was not found to be a distinguishing factor 
between disease subtypes [267]. Considering the downstream effects of ROR1 signalling upon 
tight junction associated genes, the effects that WNT5A exerts upon pro-inflammatory cytokine 
release when bound to FZD5 and the implications of the creation of a transcription start codon 
created by rs7527017, ROR1 should be considered for future genotyping and functional studies in 
larger cohorts.  
Examination of the functional annotations ascribed to all genes in the top hits of the SKAT 
Common Rare analysis identified genes that function in pathways such as autophagy and other 
immune responses that may contribute towards TBM pathogenesis. One such gene identified was 
autophagy-related 10 (ATG10). Autophagy is a process whereby cytosolic components such as 
damaged organelles are phagocytosed and subjected to lysosomal degradation [268]. ATG10 
specifically functions as an E2-like enzyme that mediates ubiquitin modifications in phagosomal 
maturation and cargo recruitment [269]. The role of autophagy in TB is well established as a 
method for the persistence and evasion of killing mechanisms by M.tb [270]. Investigation into the 
effect of ATG10 SNPs on gene function and consequent susceptibility to M.tb infection have been 
assessed [270]. No association was found for any of the SNPs studied, however, increased IL-8 
production was observed in carriers of the rs1864183 SNP, p = 0.04. This result is interesting in 
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the context of TBM as IL-8 concentrations have been found to be significantly increased in the 
CSF prior to TBM treatment and have been suggested as a potential biomarker for differential 
diagnosis [271]. SNP genotyping and functional knock-out studies of the ATG10-mediated 
expression of IL-8 in a TBM cohort or model organisms may aid in determining the role of ATG10 
in TBM disease.  
Three additional genes were identified in the SKAT Common Rare analysis. These 3 were mainly 
involved in innate immune system signalling pathways functioning in a regulatory capacity or as 
signal transducers. The first of these, interferon induced transmembrane protein-2 (IFITM2), has 
been shown to mediate antiviral responses in previous investigations [272–275]. Studies assessing 
its effects during M.tb infection led to an expansion of its functional properties in that a role in the 
restriction of M.tb infection was identified and described [276]. Through the use of IFITM1-3 
knockdown using RNA interference, significantly increased growth of M.tb was observed in both 
monocytic and alveolar cell types [276]. Individual overexpression assays were then conducted to 
determine the independent effect on M.tb survival in these cells and IFITM2 displayed a 24.7% 
reduction in growth. Expression of IFITM genes was found to be mediated by both TLR2 and -4 
receptor signalling upon M.tb recognition. IFITM2 specific expression was observed through both 
the TLR receptor pathway and independently through the IL-6 and TNF-α pathways [276]. This 
demonstrates a redundancy measure for IFITM2 signalling upon M.tb recognition suggesting an 
important role in M.tb containment. Further investigations have demonstrated the co-localisation 
of IFITM3 with late M.tb phagosomes and the overexpression of IFITM3 has been shown to 
contribute towards phagosomal acidification. In the case of IFITM2, co-localisations have not been 
assessed. However, given the redundancy measures resulting in its expression and its demonstrated 
role in M.tb containment it cannot be ruled out as possibly playing a role in TBM disease 
development warranting its inclusion as a candidate gene.  
The complement system is a part of the innate immune system through which complement proteins 
enhance bacterial killing and is mediated by phagocytic cells [277]. Phagocytes are stimulated 
through complement protein cascades leading to the recruitment of additional phagocytic cells and 
increased immune inflammation [277]. The complement system is activated through three 
independent pathways namely; the classical, lectin and alternative pathways [277]. Complement 
component 4 binding protein alpha (C4BPA) functions in an inhibitory capacity upon the 
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complement pathway by preventing the assembly of the C3 convertase enzyme complex for the 
classical and lectin pathways (C4bC2a). This is coupled with the accelerated degradation of the 
C3 complex [278]. C4BPA proteins also serve as co-factors to serine protease factor I (FI) to 
induce C4 cleavage in either fluid phases or deposited upon cell surfaces, thereby inhibiting 
complement system activation through either the classical or lectin pathways [278]. Despite the 
host protective roles that C4BPA proteins exert, they may also be captured on the surface of 
pathogens thereby rendering pathogens resistant to the effects of the complement system [279]. 
Complement activation in the lung during M.tb infection is mainly induced through the classical 
complement pathway [280]. C4 proteins were highly expressed in pTB patients when compared 
to control individuals. This was coupled with concurrent expression of CRP which has been shown 
to target C4BPA proteins and assist in the modulation of complement inhibition [280, 281]. 
C4BPA proteins have also been linked with the pathogenesis of other forms of meningitis caused 
by N. meningitidis as activation is also mediated by the classical pathway [282]. C4BPA binding 
to the cell surface of N. meningitidis was observed and cell surface binding was enabled through 
binding to bacterial Porin A (PorA) subunits [282]. Critically, this binding enabled bacterial 
resistance to the complement system as C4BPA remained functionally active even in its bound 
state and was able to mediate the inhibition of the complement system [282]. Associations with 
protection against N. meningitidis infection have been found between Complement Factor H 
(CFH) (p = 2.2x10-11 [OR = 0.64, 95% CI: 0.56-0.73]) and additionally with Complement Factor 
H Receptor 3 (CFHR3) (p = 4.6x10-13 [OR = 0.63, 95% CI: 0.55-0.71]) [283]. Both CFH and 
CFHR3 proteins are inhibitors of complement system activation which act along with C4BPA to 
modulate the complement response [283]. This study demonstrates that SNPs in genes encoding 
inhibitory proteins of the complement system may contribute to host protection against disease as 
they are unable to be captured on the cell surface of pathogens thus allowing full host complement 
activation. CFH proteins have been shown to be captured on the cell surface of  N. meningitidis to 
evade host complement-mediated phagocytosis [283]. Functional studies have shown a distinct 
link between M.tb and other forms of bacterial meningitis with the complement system and it 
represents a genuine method of immune subversion. The effects of this relationship still require 
assessment in the setting of TBM and SNPs in other complement system genes, particularly 
C4BPA, upon host susceptibility require investigation.     
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The recognition of microbial PAMPs is critical in mounting an efficient immune response against 
M.tb infection. One of these critical pathways of PAMP recognition is the TLR signalling pathway. 
TLR recognition of PAMP induces signal transduction through adapter proteins MyD88 and IRAK 
[284]. The IRAK gene family consists of IRAK1 and IRAK4, both of which are active kinases and 
2 inactive kinases IRAK2 and IRAK-M (IRAK3) [285]. The expression of IRAK-M is restricted to 
macrophage and monocyte cell types, whereas the other IRAK proteins display ubiquitous 
expression [284]. IRAK-M is a negative regulator of the TLR signalling pathway by preventing the 
dissociation of the IRAK1-IRAK4 complex from the MyD88 adapter protein [284]. In doing so, 
this prevents the formation of IRAK-TRAF6 complexes which continue the signalling cascade 
leading to the production of pro-inflammatory cytokines such as IL-12 p40 and TNF-α [284, 286]. 
In IRAK-M -/- cells observable increases in resultant cytokine production following TLR 
stimulation was noted. This was coupled with increased inflammation which was detrimental to 
the host [287]. Studies into the specific role of IRAK-M in M.tb infection have shown a marked 
decrease in Th1 immune responses in the lung [288]. This decrease is mediated by the DNAX-
activating protein 12kDa (DAP12) transcription factor which is required for IRAK-M expression, 
which in turn induces IL-10 production, an anti-inflammatory cytokine, leading to the 
immunosuppressed phenotype of antigen presenting cells [288]. This immunosuppressed 
phenotype was also observable through concurrent low-levels of nitric oxide synthase 2 (NOS-2) 
protein expression that aids in bacterial clearance [285]. The DAP12/IRAK-M/IL-10 axis therefore 
represents a susceptibility pathway in TB pathogenesis, the effects of which have not yet been 
elucidated in TBM infected patients. Considering the effects of TB with respect to the suppression 
of the Th1 response, mediated in part by IRAK-M expression, future investigations using SNP 
genotyping should be done to determine association of IRAK-M SNPs with pTB or TBM 
susceptibility. In addition, investigation into the tandem effects of SNPs in IRAK-M, C4BPA and 
IFITM2 should be undertaken to determine their overall effect on innate immune system function 
in TBM patients.  
In 2 of the analyses conducted in this study, secretion regulating guanine nucleotide exchange 
factor (SERGEF) was highlighted. Besides the functional annotation of being a guanine exchange 
factor, little is known about SERGEF function. SERGEF was identified by both SKAT analyses, 
while SKAT-O assigned an unadjusted p-value of 5x10-3 and tested a single rare SNP. SKAT 
Common Rare analysis showed a lower p-value of 4x10-4, likely attributable to 3 SNPs being tested 
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compared to a single SNP, rs377166311, which was the only shared SNP between analyses. The 
other two SNPs tested by SKAT Common Rare (rs10788 and rs1528) were both filtered out of the 
SKAT-O analysis due to their MAF being 0.13 according to the 1000 genomes, ESP6500 and 
ExAC databases [192–194].  
The fact that both SERGEF was highlighted in multiple analyses increases the possibility that this 
gene, and in particular the SNPs attributed to the gene, may play a role in TBM pathogenesis. 
Assessment of the functional role of SERGEF in TBM still requires investigation. While it may be 
possible that SNPs found in the exome sequencing may tag SNPs that were found in the top hits 
of the GWAS or vice-versa, additional validation in a larger cohort of these results is necessary.  
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Chapter 4: Genome-Wide Association Study  
4.1 Introduction 
Most sites in the genome are consistent across all humans, but approximately 10 million (1%) of 
all loci are polymorphic, accounting for the variation between individuals [289]. Differences in 
allele frequency have been observed between population groups as well. This variability in allele 
frequency accounts for inter-population differences and consequent variation observed in disease 
susceptibility between populations [290].  
Genotyping arrays from Affymetrix and Illumina both utilise the hybridisation of fragmented 
single-stranded genomic DNA to array probes designed to interrogate a specific site sub-sequence 
(see Figure 4.1) [289]. Hybridisation signal intensity is then assessed on a per-probe basis to 
determine the affinity between the target and probe sequence. Processing and analysis of raw 
intensity readings often lead to genotyping accuracies of over 99.5%.  
SNP selection for arrays is a major hurdle faced during design due to space constraints. Selection 
strategies are therefore geared towards the inclusion of SNPs previously known to be associated 
with particular diseases that share similar pathologies. The Illumina® Infinium Multi-Ethnic 
Genotyping Array (MEGA) (San Diego, CA, USA) was recently designed in conjunction with 
asthma studies of African ancestry individuals in the USA (CAAPA), the consortium of Population 
Architecture in Genomics and Epidemiology (PAGE) and from phase 3 of the 1000 genomes 
project. SNP selection included functionally relevant SNPs and those previously associated with 
asthma and other respiratory diseases such as TB. Amongst these, select genome-wide tag SNPs 
were selected to increase the power for detection of association and exome sequencing content 
from over 12 000 individuals. Given the necessity for replication of associations with complex 
diseases across population groups, SNP content from African-specific ancestries were included. 
In total the number of SNPs included was 1.7 million, making it the optimal choice for use in 
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Use of the MEGA represents a unique opportunity to assess the contribution of common SNPs to 
susceptibility with TBM.  As mentioned previously, these SNPs often  display a minor allele 
frequency above 0.05 with moderate to low effect sizes contributing to disease associations [166]. 
As the name implies common SNPs are more frequently observed in the population. This therefore 
requires a smaller sample size to attain a similar study power than would be required for rare SNPs. 
For this arm of the study, a GWAS was performed to determine if any of the SNPs present on the 
MEGA array are associated with susceptibility to TBM. This study represents the first GWAS 
performed on a TBM patient cohort.  
A key concern in TBM research concerns the initial phase of pathogenesis. Crucially the method 
of entry for TBM has not yet been elucidated. Hypotheses for the predicted entry routes range from 
nasal entry bypassing the lungs and therefore being independent of pTB, to pulmonary 
Figure 4.1: An overview of the Affymetrix (a) and Illumina (b) SNP interrogation methods. (a) Affymetrix 
probes are 25-mers for the interrogation of both SNP alleles, thereby allowing probe binding irrespective 
of SNP genotype. (b) Illumina probes are 50-mers of sites adjacent to the SNP of interest. SNP 
interrogation is performed through single base extension complementary to the allele included on the 
DNA strand. Adapted from [298]. 
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dissemination following pTB infection [20]. To gain further insight into possible SNP-mediated 
effects that may contribute to TBM development, a GWAS was performed between TBM patients 
and pTB patients using the Illumina® MEGA.  
 
4.1.1 Aims  
1. To perform a GWAS between TBM patients and healthy control individuals to identify 
SNPs associated with susceptibility to TBM. 
2. To perform a GWAS between TBM patients and pTB patients to determine if any SNPs 
are associated with progression from active pTB to TBM, and therefore possibly aid in 
dissemination to the CNS.  
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4.2 Methods and Materials 
4.2.1 Sample selection for genotyping 
A total of 1 000 DNA samples were genotyped on the Illumina MEGA platform (Illumina San 
Diego, CA, USA). These were divided into three groupings based on disease status: the entire 
cohort of 123 TBM samples, 400 pulmonary TB patient samples and 477 healthy controls (Table 
2.1). The 10 cases and controls used for exome sequencing were included in the MEGA genotyping 
sample pool. With the available sample size, we had 82% power to detect an association  with an 
odds ratio of 5, a MAF of 0.01, and a disease prevalence of 1% as per the CaTS power calculator 
[291]. PTB and healthy control samples were selected according to DNA quality metrics (see 
section 3.2.1). All TBM samples were included for genotyping to maximise numbers. DNA 
samples were diluted (60ng/µl) and sent for genotyping at the Hussman Institute for Human 
Genomics (HIHG) (University of Miami, Florida, USA).  
Quality control measures were performed on all samples at HIHG. Samples were subjected to 
agarose gel electrophoresis on a 0.8% agarose gel (Conditions: 100V for 1 hour, λHind III ladder) 
to assess the state of DNA degradation after shipping. Any samples that displayed significant 
degradation that would render results questionable were replaced with fresh aliquots (17 samples). 
Post quality control procedures, 995 samples and 11 HIHG controls were submitted for 
genotyping.      
4.2.2 Data Quality Control 
SNP genotyping microarrays are a powerful technology enabling the simultaneous genotyping of 
millions of SNP positions in the human genome. However, the complicated nature of the process 
introduces the potential for variation that can affect data analysis and results. In order to maintain 
consistency during analysis, it is crucial to control for variations between datasets using quality 
control procedures to ensure reproducible and high-quality data [292]. 
Genotype clusters were called on a per SNP basis at HIHG using cluster files generated by the 
Population Architecture using Genomics and Epidemiology (PAGE) II consortium in the 
genotyping module of Genome Studio version 2011.1 (Illumina, San Diego, CA, USA). 
Additionally, filters for SNPs with a call rate less than 85%, more than 2 replicate errors, cluster 
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separation values less than 2% or heterozygosity rates greater than 80%, were excluded. The 
genotypes were called by collaborators at Stanford University (CA, USA) and genotyping data for 
1 552 576 SNPs was received.  
During genotypic clustering analysis, 10 individuals were identified as having poor quality 
genotyping (GenCall score > 0.15) and were subsequently removed from the analysis. Using 
functions of PLINK v 1.07 [200], internal genotyping controls and pTB cases were removed from 
the dataset and new files created containing the TBM cases and healthy controls. This process left 
a total of 118 TBM cases and 440 healthy control individuals with genotyping information for 
quality control procedures. To remove single instances of duplicated SNPs the .bim file was sorted 
and unique values extracted. Improperly mapped SNPs are recorded as mapping to chromosome 
0 by default and were removed using PLINK v1.07 [200].  
Sex discordance between the user-defined .fam file and the genotyping information can be a 
confounding factor in downstream analyses, as males are more susceptible to TB [293, 294]. Sex 
discordance was calculated on a per-individual basis using PLINK v1.07 [200], where individuals 
with discordant sex information were corrected based on sex chromosome genotypic data [292]. 
Individuals with persistent sex discordance between the datasets were removed (n = 12). A search 
for duplicated samples was conducted with none found. As only autosomal regions are of interest 
in this study, sex chromosomes were removed using PLINK v1.07 [200], 49 865 SNPs were 
removed. After pre-QC dataset analysis, 1 465 892 SNPs in 116 TBM cases and 430 controls 
remained, of which 190 were male and 356 were female.      
4.2.2.1 Sample QC 
QC procedures for data on a sample level are critical to ensure consistency and quality of data for 
every individual in the study. Several quality control measures are therefore assessed to prevent 
the inclusion of outliers and thereby introduce sources of bias to the study. Issues such as 
insufficient sample concentration, contamination or labelling errors are all possible confounders 
in a genome-wide study and thus need to be controlled for during sample QC.  
Missing information can lead to the introduction of outliers and the relative levels of missingness 
serve as a good indicator of overall genotyping quality [292]. Missingness assessments were 
carried out in PLINK v1.07 [200] at both a per-sample and per-SNP basis (see 4.2.2.2 SNP QC). 
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A maximum level cut-off of 0.1, corresponding to 10% as a proportion of missing information 
(90% genotyping rate) was used as a filter – no individuals were removed.  
Heterozygosity is a relative measure to compare heterozygous vs homozygous loci per individual. 
Inflated measures are often indicators of possible sample contamination. Conversely, reduced 
levels of heterozygosity are indicative of possible consanguinity [295]. Cut-off levels of 2 standard 
deviations from the mean are recommended. However, due to the tight clustering of heterozygosity 
levels, 0.17 and 0.225 were used as more stringent minimum and maximum cut-offs, respectively. 
No individuals were removed from the analysis using these levels.  
Related individuals introduce bias through overrepresentation of certain genotypes and will 
therefore skew both the allele frequencies in the sample population and the genotypic distributions 
observed. Identification of related individuals is determined by the average proportion of shared 
alleles between individuals using identity by state (IBS) calculations. The dataset was pruned for 
linkage disequilibrium (LD), a phenomenon where SNPs do not segregate independently during 
recombination, in a 50 kilobase (kb) window at a maximum r2 correlation of 0.2 prior to IBS 
calculation [296]. The expectation is that a greater proportion of alleles that are identical by state 
will be shared between related individuals, implying identity by descent (IBD). Monozygotic twins 
and duplicates in the dataset would show an IBD of 1, first-degree relatives would show an IBD 
of 0.5 and IBD for second-degree relatives would be 0.25 [292]. Only 1 individual from a pair of 
related samples that showed IBD above 0.185 was removed. This IBD threshold represents a 
boundary halfway between second- and third-degree relatives. Using PLINK v1.07 [200], 37 
individuals were removed, leaving 114 cases and 395 controls for downstream analysis. 
Population homogeneity is critical when conducting GWAS as differences in ancestral population 
contributions between individuals may skew association results due to differing allele frequencies 
[292]. Assessments of population homogeneity are carried out using principal component analysis 
(PCA). The aim of PCA is to produce uncorrelated principal components from a dataset of 
variables that may be correlated with one another, with the first principal component accounting 
for the greatest proportion of observed variation in the dataset [297]. Eigenvectors were calculated 
from the data using PLINK v1.9 and the first 4 principal components plotted against one another 
[298]. Individuals of similar ancestral contribution produced clusters on the resultant PCA plot 
and cluster definition between cases and controls were compared. Slightly increased variation was 
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observed in the case dataset compared to controls as a result of the differences in ancestry between 
case individuals from different populations, however, none deviated sufficiently to be removed 
from downstream analyses. Thus 114 cases and 395 controls were retained in the analysis of whom 
177 were male and 332 female.   
4.2.2.2 SNP QC 
Per-SNP QC ensures the use of only highly accurate genotyping data, consistent across all study 
subjects. To this end, sufficient study power is required to identify and investigate potential SNP 
associations. Study power is dependent upon the sample size used in the experiment and directly 
influences the MAF thresholds that are able to be investigated using the given sample size [299]. 
Therefore an increase in sample population increases study power and allows for the investigation 
of SNPs with lower MAFs [300]. MAF calculations were performed using PLINK v1.07 [200] 
across all SNPs and a filter to retain all SNPs above 5% MAF was used. This procedure removed 
769 140 SNPs from the analysis, retaining 696 752 SNPs. This is expected, due to the number of 
low frequency SNPs found on the MEGA.  
To retain a high genotyping rate and therefore confidence in genotypic calls, SNPs with missing 
genotype data were removed from the analysis. This reduces the potential for the discovery of false 
positives during association testing [292]. SNP missingness was previously calculated during 
sample QC using PLINK v1.07 [200] and a threshold of 0.1 missingness was applied to retain only 
SNPs with higher than 90% genotyping call rate. This removed 9 659 SNPs to retain 687 093 SNPs 
in the dataset.  
In study settings where case and control study samples have been drawn from different areas, it is 
common practice to assess missingness differentially between the two groups as significant 
deviations may introduce bias [292]. Cases and controls were split and their relative SNP 
missingness assessed using PLINK v1.07 [200] at a threshold of 0.1, as previously discussed. 
Differentially missing SNPs (n = 6 597) were removed from both datasets using PLINK v1.07 
[200] from both datasets to reduce the likelihood of confounding association results, leaving 680 
496 SNPs.  
Hardy-Weinberg Equilibrium (HWE) on a per-SNP basis was considered as severe deviations 
from its fundamental principles can point towards genotype calling error [292]. However, certain 
SNPs may be under the effects of selective pressure in the case group and therefore may contribute 
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to susceptibility. Therefore only the control group was assessed for severe HWE deviations using 
a significance threshold of p < 0.05 [292]. HWE calculations were performed using PLINK v1.07 
[200]. This omitted 54 790 SNPs that deviated significantly, leaving 625706 SNPs for analysis at 
a total genotyping rate of 0.998 in 114 cases and 395 controls of which, 177 were male and 332 
female.  
4.2.3 Admixture Analysis 
The inheritance of particular genomic portions differs between individuals as a function of the 
contributions to their pedigree by ancestral populations [301]. In admixed populations, genetic 
contributions from ancestral populations vary between sampled individuals affecting allele 
frequencies. This can produce false-positive or false-negative association signals if not accounted 
for in statistical testing [302]. Admixture mapping was performed using Admixture v1.3.0 [303] 
and the proportions calculated included as covariates during association testing. 
The samples selected in this study were selected from different populations with varying ancestral 
population contributions, warranting statistical correction. Using self-reported population 
information and mother-tongue language information, proxy populations for the sample set were 
selected. Proxy populations were required due to the lack of an appropriate SAC reference dataset. 
These populations were selected based upon previous population genetic analyses of the SAC to 
determine the best ancestral populations, thus principal component analysis was not used for 
correction of downstream analyses [154, 304, 305]. This approach has been used in previous 
GWAS studies using this population [306]. PCA analysis was, however, conducted by merging 
study individuals with reference samples from all the available populations of the 1000 Genomes 
Project (Appendix 3) [307]. Downstream analyses were corrected for using ancestry proportions 
calculated using Admixture v1.3.0 [303].  Due to the SAC being the predominant population in 
both the case and control groups, five proxy populations were chosen for use in admixture 
calculations to account for the 5-way admixture in the SAC. The five proxies were: Khomani San 
from Upington, South Africa (Collaboration with Dr. Henn, Stony Brook University) Caucasian 
Europeans from Utah, USA (CEU), Luhya from Webuye, Kenya (LWK), Gujarati Indians from 
Houston, Texas, USA (GIH) and Han Chinese from Beijing, China (CHB) from HapMap phase 3 
data [308]. The five proxy populations were also useful for case-group individuals who self-
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identified as either of Caucasian or Xhosa origin as the CEU and LWK could be used as proxies, 
respectively.  
Proxy individuals were merged with study individuals using PLINK v1.07 with each proxy 
population being represented by equal numbers of individuals [200]. SNP overlap was determined 
between the proxy and study individual datasets using the R programming environment [201] with 
only the overlapping 198 689 SNPs retained. Strand flips were identified between SNPs of the two 
datasets. These were rectified using the flip scan function of PLINK v1.07 [200] and the datasets 
were merged.  Fifteen SNPs were removed since these strand flips could not be corrected due to 
the presence of three alleles. Genotyping quality was highlighted as being 0.54 due to the amount 
of missing data introduced when both datasets were combined. This was due to the use of different 
genotyping platforms used between the proxy and study datasets. To improve the genotyping 
quality, MAF filtration above 5% and missingness assessments (missingness rate >0.1) were 
performed using PLINK v1.07 [200] improving quality to 0.99. To increase computational 
efficiency during admixture calculations the assessment of independent SNPs, LD pruning using 
a 50kb window, a 10bp step-wise shift and an r2 cut-off of 0.2 was performed.  
Admixture v1.3.0 was run using a supervised analysis wherein reference HapMap individuals were 
assigned to population groups prior to analysis in an additional .pop file [303]. This allowed for 
the use of reference samples as a training dataset for the resultant analysis and enables efficient 
admixture calculation of study individuals. A default cross validation measure of 5 was used and 
a K-value of 5 was used to denote the assumed 5 ancestral populations of the study samples. 
Ancestral proportion estimations were later used as covariates in association analysis to account 
for the differing ancestral proportions between study individuals (Figure 4.2).  
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Figure 4.2: Overview of quality control procedures used during MEGA SNP genotyping array SNP 
prioritisation. Quality control cut-offs and procedures are included for both sample and SNP QC as well as 
admixture analysis. 
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4.2.4 Genome-Wide Association Analysis: TBM cases vs. Healthy Controls 
The basis for determining statistical association of a SNP with a disease hinges upon the 
differences in allele frequency between case and control groups [190]. This does not imply 
causality, however, as the SNP of interest may be in LD with the truly causal SNP. Sample 
heterogeneity has to be controlled for prior to association analysis to prevent confounding of 
association results [309]. 
To that end, a covariates file containing information pertaining to potential confounding factors 
such as gender and ancestral proportions per-sample was created for use during analysis. In the 
case of ancestral proportions, only the 4 ancestries with the largest contributions were included as 
covariates, as including all 5 would induce perfect separation of the data. The East Asian ancestry 
(GIH) was excluded, as its average of 4.6% across all study individuals was the lowest. Age was 
not included as a covariate in the analysis due to the separation it induces in the data as cases were 
significantly younger than controls.  
To incorporate all covariates into the association testing model, a logistic regression procedure 
was used to test for association under the additive model (see Figure 4.3). Logistic regression 
models were created with the log odds of disease representing the response variable which was 
predicted by additive combinations of genotype values and covariates [310]. Logistic regression 
was performed using PLINK v1.07 incorporating the 4 contributing ancestral populations and 
gender as covariates in an additive model [200]. Additive models assume a disease model where 
additional copies of the alternate allele increases the log odds ratio by an equal, additive amount 
[311]. 
During association testing many hypotheses are tested simultaneously, increasing the likelihood 
of false-positives (Type-I error). Therefore, corrections for multiple testing should be done. 
Multiple testing adjustment was done using PLINK v1.07 [200] during association testing. The 
correction procedures used independently were Bonferroni adjustment, Sidak single-step and step-
down procedures, Holm-Bonferroni step-down procedure and both Benjamini and Hochberg and 
Benjamini and Yekutieli False Discovery Rate (FDR) measures. To account for the number of 
tests performed, a significance level cut-off of 7.99 x10-8 was used.   
Following the analysis, the top hits were investigated to glean an understanding of the genes and 
regulatory regions that may be affected by changes to the nucleotide sequence. This was done 
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using VEP accessible via the Ensembl genome browser [216]. Additionally, transcription factor 
binding site annotations were accessed using the UCSC Table Browser facility (Figure 4.3)  [312].   
4.2.5 Genome-Wide Association Analysis: pTB cases vs TBM cases 
One of the key unanswered questions in the field of TBM research hinges on the precise method 
whereby M.tb is contained in the lung of patients who develop pTB while in a subset of active TB 
cases, dissemination to the bloodstream and eventually the CNS occurs. The host genome is likely 
to influence this phenomenon. A dataset containing the 114 post-QC TBM cases was compared to 
the 382 post-QC pTB cases both genotyped on the Illumina® MEGA (San Diego, CA, USA). Both 
datasets were subjected to identical QC procedures as outlined previously (section 4.2.2 Data 
Quality Control). Differential missingness calculations were performed to improve the genotyping 
quality to above 90% in both datasets individually, leading to the removal of 251 SNPs from the 
pTB dataset and 0 from the TBM dataset. PTB cases were then included in the analysis as 
‘controls’ to facilitate association using PLINK v1.07 [200]. After merging using PLINK v1.07 
[200], 271 males and 225 females were present in the dataset, with genotyping information for 575 
742 SNPs. Covariates for gender and the 4 ancestral proportions were included as before.  
GWAS was subsequently performed upon the merged dataset under an additive model as 
implemented in PLINK v1.07 (Figure 4.3) [200]. The analysis was adjusted for gender and the 4 
ancestry proxies with the largest proportions: European (CEU), San, Luhya from Webuye, Kenya 
(LWK) and Gujarati Indians from Houston, Texas, USA (GIH). Age was not adjusted for as a 
covariate for reasons outlined previously. Odds ratios were calculated along with their 
corresponding 95% confidence intervals on a per-SNP basis. All results were adjusted for multiple 
testing as before during analysis. A significance cut-off of p =8.68 x10-8 was used.   
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Figure 4.3: Procedures undertaken to set up the logistic regression models for the 2 GWAS analyses. GWAS 
= Genome-Wide Association Study, VEP = Variant Effect Predictor, CEU = Europeans from Utah, USA, LWK 
= Luhya from Webuye, Kenya, GIH = Gujarati Indians from Houston, Texas, USA, SAN = San individuals 
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4.3 Results 
4.3.1 GWAS: TBM cases vs. healthy controls 
No significant associations with TBM susceptibility were found. The lowest p-value was that of 
rs77857429 (p = 5.68x10-6 [OR = 4.28; 95% CI: 2.28-8.02]), an intronic SNP located in the 
Glucosylceramidase Beta 3 (GBA3) gene. Given the hypothesis generating nature of the study, an 
exploration of the top hits of the data was conducted. This was done to minimise false negative 
associations, but does expose the results to false positives. Surrounding genes and possible 
regulatory regions at each SNP were investigated to determine if any SNP localised to a regulatory 
region may affect the binding efficacy of any transcription factors, thereby influencing gene 
expression. The 10 SNPs with the smallest unadjusted p-values are shown in Table 4.1. 
Table 4.1: Exploratory dataset for the TBM cases vs. healthy controls GWAS  
 
 
Four of the SNPs listed in the top hits were localised in transcription factor binding sites. Table 
4.2 shows the gene each SNP is localised to including the type of SNP and any transcription factor 
binding sites that it may affect.  
 









Odds Ratio  
[95% CI]b 
4 rs77857429 22804085 5.68x10-6 7.17x10-6 1 4.28 [2.28-8.02] 
17 rs3760495 684729 9.17x10-6 1.15x10-5 1 2.72 [1.75-4.24] 
17 rs2273454 685640 9.17x10-6 1.15x10-5 1 2.72 [1.75-4.24] 
17 rs2750007 677226 1.50x10-5 1.85x10-5 1 3.94 [2.12-7.33] 
3 rs17046322 6952739 1.82x10-5 2.24x10-5 1 2.7 [1.71-4.25] 
4 rs1511144 127535445 2.03x10-5 2.49x10-5 1 2.27 [1.56-3.3] 
10 rs114255276 14825449 2.03x10-5 2.5x10-5 1 2.97 [1.8-4.89] 
18 rs6565824 73487088 2.25x10-5 2.75x10-5 1 0.41 [0.27-0.62] 
22 rs1127000 50716167 2.44x10-5 2.99x10-5 1 2.24 [1.54-3.26] 
12 rs10774604 111168743 2.57x10-5 3.14x10-5 1 3.67 [2-6.73] 
a. CHR = Chromosome 
b. CI = Confidence Interval  
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Table 4.2: Localisation of each of the top hit SNPs from the GWAS: TBM cases vs. healthy controls  
 
None of the highlighted SNPs were found to be located in exons and all were either intronic or 
intergenic. The Plexin B2 gene (PLXNB2) encodes several transcripts and, depending on the 
transcript, the rs1127000 SNP is either a splice site variant or a synonymous SNP. However, using 
Variant Effect Predictor (VEP) software, rs1127000 was predicted to be of low effect when all 
transcripts were considered [216].  
4.3.2 GWAS: pTB cases vs. TBM cases 
No significant associations were identified when comparing the two cases groups to assess 
progression from pTB to TBM. The SNPs listed in Table 4.3 are the top hits of the analysis and 
using a significance threshold of p=8.68x10-8 no SNPs are close to the significance threshold. The 
SNP with the lowest p-value was rs2679308, located in an intron in LOC102724084, an 
uncharacterised gene. The p-value of rs2679308 was p=5.11 x10-6.  
A dataset of the top hits of the analysis was then used for exploratory purposes. This increased 
threshold means that the likelihood of false positives is high. This dataset in Table 4.3 serves as a 
safe-guard to avoid false negative results and may provide additional SNPs for genotyping in larger 
cohorts.  
 
SNP Gene Symbol Type of SNP Transcription 
factor binding 
sites 
rs77857429 GBA3 Intronic N/A 
rs3760495 GLOD4 Intronic CTCF, RAD21, 
SMC3 
rs2273454 GLOD4 Upstream of gene POLR2A, SAP30, 
TCF3 
rs2750007 GLOD4 Intronic FOXM1, RELA 
rs17046322 GRM7 Intronic N/A 
rs1511144 LOC102724210/RBM48P1 Intergenic N/A 
rs114255276 FAM107B Promoter Flanking GTF3C2 
rs6565824 LOC100505853 Promoter Flanking N/A 
rs1127000 PLXNB2 Splice site N/A 
rs10774604 PPP1CC Intronic N/A 
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Odds Ratio  
[95% CI]b 
16 80350711 rs2679308 5.11x10-6 7.57x10-6 1 26.43 [6.47-108] 
17 51638548 rs4309447 5.72x10-6 8.44x10-6 1 3.70 [2.10-6.50] 
2 121302719 rs2140779 5.95x10-6 8.78x10-6 1 18.12 [5.17-63.5] 
17 51653566 rs2055478 8.29x10-6 1.21x10-5 1 3.61 [2.05-6.34] 
5 1442842 rs13189021 9.74x10-6 1.41x10-5 1 11.66 [3.93-34.61] 
7 138601826 rs2251220 1.31x10-5 1.89x10-5 1 3.66 [2.04-6.57] 
13 112048353 rs61966912 1.85x10-5 2.61x10-5 1 19.4 [4.99-75.35] 
4 166976065 rs1393854 1.93x10-5 2.72x10-5 1 8.61 [3.21-23.11] 
4 168490955 rs1914621 1.97x10-5 2.79x10-5 1 0.33 [0.20-0.55] 
1 168987665 rs61803268 2.02x10-5 2.85x10-5 1 8.45 [3.17-22.54] 
a. CHR = Chromosome 
b. CI = Confidence Interval  
 
 
Table 4.4 shows the exploratory dataset when comparing pTB and TBM cases with gene, SNP 
type and transcription factor binding site annotations. A single exonic SNP, rs2251220, was in the 
exploratory dataset and was localised to KIAA1549. The rs2251220 SNP induced a non-
synonymous change from a Serine to Leucine in the resultant protein. VEP analysis of rs2251220 
using SiFT and Polyphen plugins showed that the SNP was tolerated and benign with scores of 
0.1 and 0.053 respectively. The rs4309447 and rs2140779 SNPs were located in transcription 
factor binding sites. The rs2140779 SNP was located in a transcription factor binding site upstream 
of the Glioma-Associated Oncogene Family Zinc Finger 2 (GLI2) gene and is bound by the Jun 
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Table 4.4: Localisation of each of the top-hit SNPs from the GWAS of TBM cases vs. pTB cases 
 
4.4 Discussion 
4.4.1 GWAS – TBM vs. Healthy Controls 
The advent of GWAS has enabled researchers to highlight regions of the genome that confer 
susceptibility towards certain diseases. These SNPs may not be causative for the disease as they 
may tag the causative SNP. However, this procedure greatly focusses the search area for truly 
causative SNPs in the human genome. As yet, GWASs have not been undertaken in a TBM cohort 
and therefore susceptibility loci linked specifically to TBM are currently few. Many of these are 
known as a result of candidate genes that have been extrapolated from pTB. This approach is 
flawed as the two diseases follow different mechanisms of pathogenesis, despite sharing the same 
infectious bacterium.  
To gain a better understanding of susceptibility loci specific to TBM we performed a GWAS using 
the Illumina MEGA. Using logistic regression for SNP testing and correction for multiple testing 
and covariates, no significant genome-wide associations with TBM disease were detected. 
Examination of the top-hits in the analysis showed that 3 of the top 4 SNPs were located in or 
around the Glyoxalase Domain Containing 4 (GLOD4) gene. In addition to this, all 3 displayed 
odds ratios pointing towards being susceptibility factors. As yet, GLOD4 has no known function 
and has not been investigated in the context of TBM. Further investigation into their biological 
relevance showed that rs3760495 and rs2750007 were intronic and rs2273454 was located 
upstream of GLOD4 (Table 4.2). All 3 of these SNPs were located in transcription factor binding 
SNP Gene SNP Type Transcription Factor Binding Sites 
rs2679308 LOC102724084 Intronic N/A 
rs4309447 LOC100419014/RPS2P48 Intergenic FOS, JUND 
rs2140779 LOC84931/GLI2 Upstream SNP JUND 
rs2055478 LOC100419014/RPS2P48 Intergenic N/A 
rs13189021 SLC6A3 Intronic N/A 
rs2251220 KIAA1549 Exonic N/A 
rs61966912 TEX29/LOC101928616 Intergenic N/A 
rs1393854 TLL1 Intronic N/A 
rs1914621 SPOCK3/PHBP14 Intergenic N/A 
rs61803268 LINC00970 Intronic N/A 
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sites bound by multiple transcription factors. Of particular interest was rs2273454 which was 
found to be located in a binding site for RNA polymerase II. This points to the SNP being located 
in the GLOD4 promoter region and may affect gene expression. As a result, future investigation 
into possible diminished RNA polymerase II binding and therefore diminished transcription of 
GLOD4 as a result of rs2273454 should be investigated.  
Considering the sample size used in the GWAS, this lack of association is likely attributable to the 
diminished study power observed when using a study population of 123 TBM patients and 477 
healthy controls. This does not imply that these SNPs may not be associated with TBM in other 
population groups as a result of allele frequency differences or when examined in a larger sample 
size with greater statistical power to detect associations. This is however one of the largest TBM 
collections in the world and therefore represents a valuable resource for TBM research, especially 
considering the challenges involved in patient recruitment of such a rare disease. 
  
4.4.2 GWAS – TBM cases vs. pTB cases 
The mechanism whereby TBM disease is developed is one of the central questions of TBM 
research. In a subset of individuals, M.tb is not properly contained in the lung and disseminates to 
the CNS. One possible contributing factor to this phenomenon is the host genome and in particular 
differences between the genomes of pTB and TBM patients. Other factors such as M.tb strain 
differences and environmental factors will contribute to TBM development. M.tb strain differences 
have a proven role in their disseminatory capacity. The Beijing strain is considered to be more 
virulent and is the causative strain for the majority of TBM cases [109, 116]. The varying 
dissemination capacity between strains exposes a possible bias in this result as culture of M.tb 
from some TBM patient samples is not possible [313]. A link has also been shown between certain 
populations and susceptibility to certain M.tb strains thus further complicating the problem [314]. 
Natural variation of the host genome is expected between all humans, however, SNPs in key 
immunoregulatory genes may assist in answering this question central to TBM research.  
The GWAS of TBM cases compared to pTB cases did not yield any SNPs that were associated 
with progression from pTB to TBM (Table 4.3). Exploratory analysis into the top hits of the 
GWAS revealed a single exonic SNP, rs2251220. Assessment of the substitution induced by 
rs2251220 using the prediction tools SiFT and Polyphen-2 determined that the non-synonymous 
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change from a Serine to Leucine was benign and tolerated respectively [265, 266]. SNP selection 
for the MEGA array was based primarily around the selection of tag-SNPs therefore the location 
of the SNP being investigated is often not the true location of the SNP that is driving the effects 
seen in this study. Therefore one cannot discount that these SNPs may be associated with TBM 
progression in other populations with different allele frequency spectrums. In that case, the LD 
structure surrounding each SNP would require investigation to determine the SNP truly driving 
the association and determine its biological relevance. 
In this study both GWAS studies suffered from low sample numbers and were particularly affected 
by the age difference between the cases and controls. This may have impacted upon the results of 
the study and may be a contributing factor to the negative results of the logistic regression. In 
addition, the use of the full TBM cohort for the GWAS introduced some fine-scale population 
structure as the cases were not all from the SAC and some were from the Xhosa population. 
Previously covariates that were correlated with the phenotype of interest were corrected for by 
including these in logistic regression models [315]. Logistic regression testing using case and 
control cohorts are vulnerable to confounding by population structure and stratification, the result 
being an increase in test statistics and a higher false positive rate [316]. However, in studies using 
binary or categorical variables where the selection of cases and controls leads to a correlation 
between the covariate and the genotype of interest, a reduction in study power will ensue due to 
an increase in the standard error [315]. Controlling for population structure in logistic regression 
is traditionally done through the inclusion of principal components as covariates during model 
construction, this considered as a broad scale adjustment [317]. Likewise controlling for the 
genomic inflation factor, a measure of inflation of the test statistic, aids in reducing the false 
positive rate. Adjustment for the genomic inflation factor is recommended when a homogenous 
population is used in the study and no significant differentiation is seen [317]. In the case of a 
stratified sample set like the one used here, a mixed model approach should be considered.  
Mixed linear models such as the variance component approach, efficient mixed-model association 
(EMMA), are often considered to be computationally intensive in datasets consisting of large 
sample numbers. This inefficiency is as a result of the need for estimation of variance parameters 
[318]. Optimisation of this process was achieved through the estimation of variance parameters 
only once per dataset as often the effect of a particular locus is often upon a trait is marginal [319]. 
Stellenbosch University  https://scholar.sun.ac.za
Chapter 4: Genome-Wide Association Study 
85 | P a g e  
 
This optimised approach is known as EMMA eXpedited (EMMAX) and is able to account for 
population structure through measures of pairwise relatedness between individuals [317]. The 
structure is controlled for through the use of an empirically calculated relatedness matrix as a 
correlation of phenotypes is expected in genetically similar individuals [318]. This approach has 
been previously applied to whole genome association studies [320–322].  Through use of a mixed 
model approach such as EMMAX, the study power would be increased and thorough correction 
for all covariates and age stratification would be possible.  This represents a viable solution for the 
structure involved in studies involving an early onset rare disease which is considered a challenge 
for patient recruitment.
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Chapter 5: Concluding remarks 
This study contributes significantly to the TB host genetics field, since we present the first exome 
sequencing study and GWAS of children with a rare form of TB, namely TBM.  The overarching 
aim of this study was to assess the contribution, if any, of common SNPs of varying frequency to 
TBM susceptibility. To this end, SKAT gene-set based analyses were used to assess the 
contribution of rare SNPs (MAF < 0.01) and their cumulative effect when combined with common 
SNPs (MAF > 0.01) from exome sequencing data. Two GWAS were performed on the Illumina® 
MEGA including samples from TBM cases, pTB cases and healthy controls. It is also the first 
exome sequencing and GWAS study to be performed on TBM patients from South Africa, giving 
insight into manifestations of TBM patients in this setting. Exome sequencing of the healthy 
controls will provide a useful resource for other researchers working with the SAC population.  
Our GWAS studies were designed to identify susceptibility loci for TBM development as either a 
primary infection or as a result of dissemination from a primary pulmonary focus. Neither of these 
analyses, however, identified any loci associated with TBM in the SAC. This is likely to be a direct 
result of insufficient study power due to small sample size.  
An association with TBM susceptibility was with CCP110 (p = 5.89x10-6) (rs3751821, rs226891, 
rs7190666) in the SKAT Common Rare analysis which assessed the cumulative effect of common 
and rare variants between TBM cases and healthy controls. This association, however, is possibly 
a false positive due to the insufficient covariate correction, but may also point towards a previously 
unknown role for CCP110. No significant associations were found with TBM infection using the 
SKAT-O gene-set association test or for the GWAS between TBM cases and healthy controls.  
The combination of all these analyses provided a number of candidate genes for future study in 
the context of TBM, some of which may lead to advances in our current understanding of TBM 
pathogenesis. These are highlighted in Table 5.1 and can in future be studied both genetically and 
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Table 5.1: The candidate genes identified in this study 
Gene Association Test Unadjusted p-
value 
Relevance 
ZFHX3 SKAT-O 4.63x10-4 SKAT-O, Lowest p-value 
CYP4F2 SKAT-O 1x10-3 LTB4 regulation 
NOD2 SKAT-O 6.71x10-3 TNF-α regulation and pathogen 
recognition 
CCP110 SKAT Common 
Rare 
5.89x10-6 SKAT Common Rare lowest p-value 
A2M SKAT Common 
Rare 
8.63x10-3 Cytokine transporter 
CX3CR1 SKAT Common 
Rare 
9.57x10-3 T and B cell recruitment, microglia 
response 
MARCO SKAT Common 
Rare 
1.75x10-3 Pathogen recognition 
ROR1 SKAT Common 
Rare 
6.60x10-4 Regulation of tight junctions 
ATG10 SKAT Common 
Rare 
8.56x10-4 Autophagy – phagosomal maturation 
IFITM2 SKAT Common 
Rare 
9.23x10-3 Innate immunity – signal transduction 
C4BPA SKAT Common 
Rare 
2.54x10-4 Complement system regulation 
IRAK-M SKAT Common 
Rare 
8.24x10-3 TLR pathway regulation 
Significant results are highlighted in bold text 
 
The innate immune system consists of a series of interacting pathways which cumulatively provide 
the human host with protection against invading pathogens. Due to the complex interactions 
involved in immunity, a certain level of redundancy between pathways is expected. This 
redundancy acts as a compensatory measure if defects in one pathway is present. While many of 
the genes listed in Table 5.1 are part of the innate immune system, their functional annotations are 
varied and not localised to any one pathway of innate immunity. Thus if any defect in these genes 
were to arise it would likely be compensated for by interacting genes. It is these redundancy 
measures which may explain why no significant associations were found in some analyses. We 
therefore recommended that the total complement of genes acting in a single pathway be 
investigated for association with disease to mitigate the effects of redundancy. This will allow 
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proper assessment of the role these genes play in innate immunity and further our knowledge of 
TBM pathogenesis. 
This study had several limitations which may affect the conclusions that can be drawn from results 
or perhaps hinder the detection of results in the first instance:  
1. Patient recruitment for the rare TBM disease phenotype is a major challenge and this 
resulted in a small sample size. This means the study did not have sufficient power to detect 
associations with variants with lower allele frequencies (1 – 5%) and small effect sizes. 
This will particularly influence the SKAT-O analysis as rare SNP association studies 
require large sample numbers in order to be sufficiently powered to detect associations 
with rare SNPs of small effects [171, 299, 323, 324]. Sample size impacted on covariate 
correction as well. Consequently correction for ancestry and age was not possible in the 
two SKAT analyses as inclusion of more than 1 covariate besides gender in the logistic 
regression induced perfect separation in the analysis. Therefore, it is possible that our 
results are enriched for Type 1 errors and these results should be validated in additional 
and larger sample sets.  
2. During quality control procedures for the MEGA SNP genotyping array, filtration for the 
retention of SNPs with an MAF >0.05 was performed. This was done in consideration of 
the sample size with the aim of retaining sufficient study power. In doing so, 499 859 SNPs 
were removed from the analysis. This represents a significant proportion of the 1.7 million 
SNPs that were genotyped originally. SNP selection methods used during the creation of 
the array likely influenced the number removed as the allele frequencies from studies on 
different populations were taken into account during SNP selection. Due to the differences 
in allele frequency between populations and the admixed nature of the SAC population, it 
is likely that the 769 140 SNPs removed were of very low frequency in the SAC population 
compared to populations used in SNP selection. 
3. Age stratification between cases and controls during sample selection will have introduced 
bias into the analysis. This, however, was unavoidable as the most susceptible age for TBM 
onset is between 0-5 years of age. In contrast, control samples needed to be of sufficient 
age to decrease the chance of TBM development. Additionally, control individuals required 
sufficient exposure to pTB to ensure that active pTB infection did not occur in these 
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individuals. This stratification in age was also noted in a Russian study of pTB wherein the 
cases were significantly younger than the control group [325]. Age stratification is often 
necessary in childhood diseases as a result of disease pathogenesis. A control group that is 
older often displays a lower risk for the phenotype of interest allowing for accurate 
comparisons. The results from both GWAS analyses were also affected by age 
stratification.  
4. The ROR1 SNP rs7527017, found in the top hits of the SKAT Common Rare analysis was 
genotyped in the MEGA genotyping data. Being a larger cohort, this represented an 
opportunity to assess its possible association with TBM, along with 108 other SNPs in 
ROR1. However, it was removed during quality control measures due to significant 
deviation from HWE (p=0.01245) in the control group. HWE deviations in the control 
group may in fact be as a result of the admixed nature of the SAC population and not as a 
result of poor genotyping [326]. This means we could not analyse this SNP in the larger 
sample set. In retrospect, the chosen threshold of p = 0.05 was likely too stringent and 
considering the MAFs in the proxy populations: CEU = 0.409, CHB = 0.32, GIH = 0.296 
and LWK = 0.04 the threshold for exclusion could have been lowered to p < 0.001 as stated 
in literature [292].   
5. The basis of exome sequencing is to sequence only the exonic regions of the genome which 
represent approximately 1.2% of the total nucleotide content [159]. The library preparation 
does involve the targeting of the 5’- and 3’UTR regions as well, with the aim of capturing 
regulatory sites. However, due to the relatively small portion of the genome that is actually 
sequenced, a limitation of the study is the genome coverage.   
6. Population structure was present in the TBM case group as the entire patient cohort was 
used for GWAS. This included Xhosa and SAC individuals and therefore introduced 
sample heterogeneity. Population structure is commonly corrected for through the 
inclusion of principal components as covariates in the testing model. In this case, correction 
using PCA was not done as ancestry components were corrected for using Admixture 
v1.3.0 using pre-determined proxy populations. However, the use of proxy populations is 
biased and does not represent an empirical assessment of the population sub-structure.  
Future studies would include the verification of the association seen between CCP110 and TBM, 
preferably in a larger cohort. If this result is verified, functional studies into the mechanisms of 
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CCP110 can be studied in the context of TBM which may identify a novel function for CCP110. 
During exome sequencing analyses 10 candidate genes were identified which function in pathways 
of the innate immune system. Several of these genes play a regulatory role in the pathway and may 
play a critical role in the regulation of the inflammatory response, a key factor in TBM 
pathogenesis and neurological sequelae. The candidate genes in Table 5.1 must be interpreted with 
caution as our knowledge of the majority of biological pathways is fragmented at best. Several 
genes may not be involved in TBM pathogenesis as a result of biological interactions or 
relationships currently unknown. Future genotyping studies to determine the association of SNPs 
in the genes listed above with increased TBM susceptibility will also determine if the genes are 
involved in TBM. These SNPs would then be followed up with functional analyses, assuming 
associations are found, which could measure expression levels and their effects upon pathway 
function in the context of TBM disease. Age stratification was a major issue in the study design 
and may have impacted upon the results obtained. It may be possible to mitigate the effects of the 
stratification by “spiking” the control group used in each analysis with a number of case 
individuals. The aim of this will be to reduce the separation induced through stratification. An 
approach such as this will lower the overall study power, but may be counteracted through the use 
of a large cohort. Additionally application of Firth penalised regression models would aid reducing 
bias caused by separation [327]. Association analyses would then take the form of trend analyses 
to determine association of SNPs with TBM susceptibility.  
Strategies to cope with small sample sizes and population structure such as mixed models would 
be an alternative to logistic regression without a significant reduction in power. Recommendations 
for future studies would include performing association testing of this dataset using a mixed model 
approach such as EMMAX as explained in section 4.4.2. The use of this will provide an unbiased 
correction for age stratification and population sub-structure, instead of using proxy populations 
for the admixture present in the SAC group.  
As an alternative solution to the age stratification between cases and controls, adult TBM cases 
with HIV can be compared to HIV positive individuals without TBM. HIV status is a known 
susceptibility factor for extrapulmonary TB and pTB development [328]. Thus, HIV positive 
controls that do not develop TBM or TB of any form must have extreme genetic resistance factors 
[329]. While sampling of such a specific and extreme phenotype is possibly more challenging than 
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the recruitment strategy employed in this study, sampling of extreme phenotypes has been shown 
to increase study power in sequencing studies [162–164].  
Under ideal circumstances the overall study design could have been modified to allow the use of 
the exome sequencing dataset as a replication cohort for findings from the GWAS. However, in 
this case this was not possible as the 10 TBM case samples that were used for exome sequencing 
were also used in both GWAS analyses. A recommendation in this case would be to perform gene-
set based association testing on the larger GWAS dataset to ascertain whether findings from the 
exome sequencing would still be present in the larger cohort used for GWAS. An advantage of 
this approach would be a significant reduction in the multiple testing burden and additionally 
would facilitate the proper correction for covariates.   
TBM remains the form of TB with the highest mortality rate and therefore represents a major 
problem for medicine worldwide. It is clear that not enough is known about disease pathogenesis 
mechanisms as critical factors such as the method of dissemination to the bloodstream and 
eventually the CNS are still unknown. TBM represents an extreme form of TB where the 
contribution of host genes and strain type are more likely to determine disease presentation than 
environmental factors. Our GWAS results support this hypothesis, since the TBM cases and pTB 
patients share similar environmental and economic circumstances. We also posit that defects 
during CNS development may contribute to TBM development rendering critical barriers such as 
the BBB or BCB vulnerable to pathogenic invasion. TB is a complex disease that has known 
environmental, bacterial genotypic and host genotypic factors which influence its presentation and 
disease severity. This is also true for TBM and certain mycobacterial strains are more often found 
to be the causative agent. However, it is also apparent that the host genotype plays a role in the 
disseminatory capacity of mycobacterial strains in patients as not all patients with these strains 
develop TBM. This suggests that polymorphisms could induce defective protection against 
infection in these patients. The subset of genes that confer susceptibility to TBM may likely 
overlap with those found to influence susceptibility to pTB, particularly those with involvement 
in innate immunity. However, differences between the susceptibility gene subsets will likely be 
apparent due to the inclusion of genes that may render the BBB vulnerable and others that may aid 
in dissemination. Through the findings of this study, it seems that SNPs of higher frequency but 
comparatively more moderate effect sizes influence the susceptibility of TBM patients, instead of 
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rare SNPs of large effect. This, however, does not imply that rare SNPs do not play a role in TBM 
pathogenesis. Three genes involved in innate immunity were identified during the exome 
sequencing analyses, namely: IRAK-M, C4BPA and IFITM2. Due to the immunoregulatory nature 
of both IRAK-M and C4BPA and the containment of M.tb by IFITM2, it is likely that these genes 
may play a synergistic role in TBM pathogenesis. Although they do not function in the same 
pathway, their cumulative effect upon the innate immune system should not be discounted. The 
results of association studies such as the one presented here may possibly contribute towards the 
identification of more susceptible individuals in the population in the future of personalised 
medicine. Through this, different vaccination strategies and treatment durations may be instigated 
to tailor treatments to the needs of the patient and hopefully protect against TBM, a disease with 
debilitating consequences even for survivors. 
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Appendix 1: Gene-sets from the SKAT-O analysis with p-values < 0.01. These gene-sets were used as input 
for IPA core analysis 
Gene-set Unadjusted P-value Number of SNPs in 
Gene-set 
Number of SNPs 
Tested 
ZFHX3 0.000463 8 8 
CYP4F2 0.001001 2 2 
PHC1 0.001624 3 2 
PSG5 0.002012 3 3 
MUC17 0.002507 6 6 
RIF1 0.002656 7 7 
PIGG 0.00357 5 5 
ESPL1 0.004212 5 5 
ITPR3 0.004462 4 4 
DCHS2 0.004487 3 3 
C2orf61 0.004728 1 1 
LHFPL5 0.005362 1 1 
MRO 0.005362 1 1 
SERGEF 0.005362 1 1 
TOPBP1 0.005781 2 2 
FARP2 0.006122 3 3 
CHL1 0.006647 4 4 
USP6 0.006652 5 5 
ADCK4 0.006676 4 4 
NOD2 0.006711 3 3 
RFX8 0.007084 4 4 
LTBP4 0.007129 7 7 
NPIPB3 0.00726 3 3 
CTAGE4 0.007659 14 11 
RPGRIP1L 0.008034 5 5 
KIDINS220 0.00829 1 1 
CC2D1A 0.008785 4 4 
ZNF107 0.008786 1 1 
ALDH3B1 0.00887 2 2 
KIAA1919 0.008925 2 2 
OR4D9 0.009327 1 1 
FSTL5 0.009362 3 3 
ESRRA 0.009365 7 7 
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KCP 0.009549 13 13 
COL11A1 0.009604 5 5 
OR1J2 0.009747 2 2 
FRMD5 0.009894 1 1 
TMEM150B 0.009907 1 1 
GCKR 0.009942 1 1 
 
Appendix 2 
Appendix 2: Gene-sets from the SKAT Common Rare analysis with p-values < 0.01. These gene-sets were 










SNPs, MAF < 
0.01 (Rare) 
Number of 
SNPs, MAF > 
0.01 
(Common) 
CCP110 5.89E-06 3 3 1 2 
OR2A5 1.49E-05 5 5 2 3 
CCNI2 0.000115 2 2 1 1 
APOBEC4 0.000146 5 5 0 5 
C4BPA 0.000254 6 6 5 1 
PLBD2 0.000272 3 3 2 1 
DOCK6 0.000274 7 7 6 1 
ZNF804B 0.000369 9 9 8 1 
SERGEF 0.000369 3 3 3 0 
LDLRAD2 0.000422 1 1 0 1 
OR2T5 0.000607 11 11 3 8 
APOF 0.000632 2 2 1 1 
ROR1 0.00066 1 1 0 1 
SLC45A2 0.000789 3 3 2 1 
CFAP44 0.000826 18 18 17 1 
ABCA6 0.000831 10 10 6 4 
ATG10 0.000856 3 3 0 3 
PAN2 0.000901 2 2 1 1 
ZFYVE16 0.001004 8 8 5 3 
CCDC18 0.001088 5 5 3 2 
PNPT1 0.001122 5 5 3 2 
PROB1 0.001234 7 7 6 1 
HAUS6 0.001368 8 8 7 1 
TMED8 0.001409 3 3 1 2 
CKAP2L 0.001452 7 7 6 1 
RSPO2 0.001503 1 1 0 1 
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RRP36 0.001523 1 1 0 1 
MARCO 0.001755 2 2 1 1 
FAM208A 0.001793 5 5 3 2 
MTAP 0.001892 1 1 0 1 
NPHP4 0.002075 10 10 8 2 
GDF5 0.002125 3 3 2 1 
EXD3 0.002176 19 19 16 3 
SMUG1 0.002186 2 2 2 0 
G6PC 0.002384 1 1 1 0 
CTAGE15 0.002459 7 6 3 3 
SPAG16 0.002536 6 6 4 2 
OXSR1 0.002593 1 1 0 1 
TNNI1 0.002677 1 1 1 0 
FAM135A 0.002685 3 3 2 1 
SLC25A39 0.002694 1 1 0 1 
TMEM19 0.002738 1 1 1 0 
ASB17 0.002918 1 1 0 1 
GUCA1C 0.002933 4 4 2 2 
IFNK 0.003147 2 2 1 1 
CYFIP1 0.003199 2 2 1 1 
KRT25 0.003233 2 2 1 1 
ARHGEF17 0.003428 8 8 7 1 
DPY19L1 0.003455 1 1 0 1 
KLK10 0.00357 2 2 1 1 
CLC 0.003578 1 1 0 1 
CNTRL 0.003599 8 8 6 2 
ANLN 0.003646 4 4 3 1 
KRT20 0.003692 2 2 1 1 
NAT9 0.003743 2 2 1 1 
EVPLL 0.003795 3 3 2 1 
TEX15 0.003905 17 17 12 5 
MYO7A 0.003988 9 9 6 3 
KHDC3L 0.004007 2 2 1 1 
MACF1 0.00429 14 14 12 2 
SRRD 0.004298 2 2 1 1 
VSIG10 0.004348 3 3 2 1 
SMCR8 0.0044 6 6 4 2 
TMCO4 0.00442 7 7 5 2 
OR6C74 0.004431 7 7 3 4 
CLSPN 0.004446 9 9 8 1 
DDHD2 0.004602 1 1 1 0 
Stellenbosch University  https://scholar.sun.ac.za
Appendices 
121 | P a g e  
 
B3GNT2 0.004623 1 1 1 0 
GNAT2 0.004625 1 1 1 0 
FAM135B 0.004678 4 4 2 2 
R3HDM2 0.004769 1 1 1 0 
BBS9 0.004783 7 7 6 1 
AK4 0.004789 3 3 2 1 
NMB 0.004869 1 1 1 0 
DDX11 0.004949 10 10 7 3 
SCYL3 0.005048 2 2 1 1 
CYBRD1 0.005057 2 2 1 1 
GPR56 0.005066 3 3 2 1 
OR7G3 0.005156 9 9 7 2 
SAMD15 0.005164 9 9 6 3 
QSOX2 0.005205 2 2 2 0 
MAP2 0.005219 4 4 3 1 
HEXA 0.005255 2 2 1 1 
GNRH1 0.005362 1 1 1 0 
ZNF133 0.005362 2 2 2 0 
PLA2G4D 0.005363 10 10 8 2 
GSDMA 0.005428 5 5 1 4 
PATE1 0.005447 2 2 1 1 
FCRL3 0.005501 4 4 3 1 
CBY3 0.005623 3 3 2 1 
TMEM211 0.005643 2 2 2 0 
OR6Y1 0.005709 5 5 4 1 
KLK2 0.005909 2 2 1 1 
CRNKL1 0.005945 6 6 3 3 
KIDINS220 0.005971 2 2 2 0 
ADCK5 0.005977 1 1 1 0 
C1orf94 0.006168 5 5 2 3 
DDX52 0.006202 2 2 1 1 
EXO5 0.006396 3 3 2 1 
PCDHA9 0.006427 13 13 7 6 
DDX43 0.006446 4 4 2 2 
HHATL 0.006594 4 4 3 1 
WSB2 0.006646 1 1 1 0 
FRMD5 0.006747 1 1 1 0 
G6PC3 0.006747 1 1 1 0 
PACS2 0.006751 5 5 4 1 
LHFPL5 0.006842 1 1 1 0 
NR5A1 0.006862 1 1 0 1 
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CCDC137 0.006928 8 8 5 3 
AGMO 0.007152 5 5 4 1 
ZFP62 0.007167 2 2 1 1 
PPY 0.007178 1 1 1 0 
GRIP2 0.007196 13 12 7 5 
CTAGE9 0.00722 11 11 9 2 
HAVCR1 0.007383 5 5 4 1 
TRDMT1 0.007401 2 2 1 1 
NLGN4X 0.007411 1 1 0 1 
PDCD1LG2 0.007552 4 3 2 1 
ZNF267 0.007637 1 1 0 1 
PPIAL4G 0.007691 9 6 3 3 
TRPM2 0.007722 12 11 10 1 
HOXC4 0.007775 1 1 0 1 
FAM71F2 0.008107 5 5 2 3 
OR2A25 0.008131 5 5 3 2 
APBB2 0.008149 2 2 1 1 
HDHD1 0.008232 2 2 1 1 
IRAK3 0.008238 4 4 3 1 
ZNF816 0.0084 5 5 4 1 
MRPL37 0.008511 2 2 1 1 
TAS2R9 0.008528 4 4 3 1 
AMER1 0.008563 1 1 0 1 
KIAA1462 0.008571 6 6 4 2 
A2M 0.008629 10 9 8 1 
TUBG2 0.008754 2 2 1 1 
OR4K17 0.008912 3 3 2 1 
CELSR2 0.008933 8 8 7 1 
PDCD4 0.009141 1 1 0 1 
IFITM2 0.009234 3 3 1 2 
C5orf42 0.009251 8 8 7 1 
C18orf21 0.009288 2 2 1 1 
GPR98 0.009304 45 44 36 8 
OR6C1 0.009453 6 6 4 2 
GSTA2 0.009478 3 3 1 2 
TMEM214 0.009542 3 3 2 1 
CX3CR1 0.009569 4 4 3 1 
UAP1L1 0.009624 5 5 3 2 
SLC36A3 0.009629 4 4 3 1 
ARHGAP9 0.009636 5 5 4 1 
AGXT2 0.009701 6 6 3 3 
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DNMT1 0.00972 1 1 1 0 
 
Appendix 3 
Appendix 3: Principal component analysis plots with TBM cases and controls genotyped on the MEGA 
array compared to reference samples from the representative populations of the 1000 genomes project. 
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